Professor Michelle Haber

Tabs

Main

Contact Category:

Conjoint

Discipline:

Paediatrics

Professor Michelle Haber obtained her PhD at UNSW in 1984, and subsequently undertook postdoctoral studies at Hadassah Hebrew University, Israel and Albert Einstein College of Medicine, New York. She was appointed as the Director of the Children's Cancer Institute (CCI) in 2000, and then Executive Director in 2003, where she is the Co-Head of CCI’s Molecular Targets and Cancer Therapeutics Theme and also heads the Experimental Therapeutics Program.

Michelle’s research is focused on developing novel approaches to treating refractory childhood cancer through identifying molecular targets that drive cancer growth and development, developing new drugs to inhibit the action of these targets, and combining existing and new drug treatments into novel therapeutic approaches that can be rapidly translated into national and international clinical trials.

School:

Sch Women's&Children's Health

Phone:

+61 2 7209 6709

Email:

mhaber@ccia.unsw.edu.au

University role:

Executive Director of Children's Cancer Institute; Co-Head, Molecular Targets and Cancer Therapeutics Theme

Qualifications:

1984 PhD University of New South Wales

1978-79 PhD qualifying program University of New South Wales

1978 BSc (Psych) Honours Class 1, University Medal University of New South Wales

2008 D.Sc. honaris causa University of New South Wales

Grants:

2020-2024 MRFF Emerging Priorities and Consumer Driven Research initiative EPCD000015) 'ZERO Childhood Cancer National Precision Medicine Program'
2020-2023 Australian Cancer Research Foundation 'The ACRF Child Cancer Liquid Biopsy Program'
2020-2023 Neuroblastoma Australia ‘MYC inhibitors to potentiate CART cell therapy
2020-2023 Cancer Australia/ The Kids Cancer Project ‘Enhanced polyamine depletion as a novel therapy for aggressive cancers
2019- 2021 Cancer Australia- 'Targeting the NAD pathway as a new therapeutic strategy for high-risk leukaemia in children'
2019- 2023 APP1159004 NHMRC Partnerships Project- 'The economic impact of precision medicine in high risk and aggressive childhood cancer'
2018-2022 Children’s Cancer Foundation- 'SIOPEN neuroblastoma clinical trials in Australia and New Zealand'
2018-2021 Children’s Cancer Foundation- 'Leveraging the SIOPEN High risk 2.0 clinical trial for high-risk neuroblastoma to understand relapse, improve residual disease detection and develop pre-clinical testing models for high-risk neuroblastoma'
2018 Cancer Australia/Medical Research Future Fund Australian Brain Cancer Mission- 'Zero Childhood Brain'
2019 Tour de Cure Foundation - 'A personalised medicine approach to the treatment of acute myeloid leukaemia in children'
2018 REG181200 – Cancer Institute NSW Research Equipment Grant- 'Australia’s first deformability cytometer – a novel tool for cancer mechanobiology and diagnosis'
2018- 2020 APP1136278 – NHMRC Development Grant- 'Multidrug Resistance Protein 1 inhibitors to sensitise cancers to chemotherapy'
2018- 2022 APP1132608 – NHMRC Program Grant- 'More effective therapeutic targeting of high risk childhood cancer: Neuroblastoma as a model'

Awards:

Honours:

2007 Member of the Order of Australia (AM) for services to science in the field of research into childhood cancer, to scientific education and to the community

2010-12 President, Advances in Neuroblastoma Research Association.

2008 Degree of Doctor of Science, honoris causa, in recognition of eminent service to the community, University of New South Wales

2015 Inaugural Fellow, Australian Academy of Health and Medical Sciences

2020 Invited Speaker, American Association for Cancer Research, Presidential Select Symposium, San Diego, CA, USA

Awards:

2011 Winner - NSW Science and Engineering Award for Biomedical Sciences

2012 Winner - Cancer Institute NSW Premier’s Award for Excellence in Translational Cancer Research

2013 Finalist - NSW Health Jamie Callachor Eureka Prize for Medical Research Translation

2014 Winner - Best Translational Research Presentation, Advances in Neuroblastoma Research Congress, Cologne, Germany

2014 Winner - Cancer Institute NSW’s Premier’s Award for Outstanding Cancer Researcher of the Year

2015 Finalist - The Australian Innovation Challenge Award, for pioneering work in improving the survival rates of children with acute lymphoblastic leukaemia

2018 Finalist - CSIRO Eureka Prize for Leadership in Innovation and Science

Research

Research activities:

Michelle’s earlier studies were amongst the first characterising the complex molecular mechanisms underlying therapy-related drug resistance. She identified the relationship between high expression of multidrug transporter gene MRP1, the malignant phenotype of neuroblastoma and poor clinical outcome – the first definitive demonstration of clinical relevance of the MRP1 gene in human solid tumours. She subsequently established high-throughput chemical screening of small molecule libraries and developed novel MRP1 inhibitors for the treatment of neuroblastoma and other MRP1-assciated malignancies. This led to a $3.1M ACRF award to establish a Drug Discovery Centre for Childhood Cancer which is now developing a pipeline of potential new drugs for treating childhood and adult malignancies.

Michelle pioneered polyamine inhibition therapy as a new approach to child cancer treatment, leading to one completed international trial in 15 children’s hospitals, one current trial open in 120 hospitals internationally, and two more being planned for neuroblastoma and for brain tumours. She and her colleagues identified targeting of the chromatin modifier FACT as a novel therapy for neuroblastoma, acute lymphoblastic leukaemia (ALL), and DIPG and based on these findings, a clinical trial using FACT inhibition, led by the Children’s Oncology Group, the largest children’s cancer study group in the world, will open this year. She was also a leader in the team developing OT82, a novel inhibitor of NAMPT and in developing NAMPT inhibitor therapy for paediatric ALL, with an adult Phase 1 open, and planning for a paediatric trial underway.

She also played a major role in developing PCR-based technology to detect the presence of minimal residual disease (MRD) in bone marrow of children with ALL, after initial cancer treatment. The prognostic value of this assay was proved in several national trials, with a large international clinical trial of 1100 children, resulting in a doubling of survival rates for children at high risk of treatment failure from <40% to >70%. This approach has now become standard of care for Australian children with ALL. This laid the foundation for establishment of the national ZERO Childhood Cancer Personalised Medicine Program. She has successfully led the development and roll-out of ZERO, to every Australian paediatric oncology facility, currently available to children with the most aggressive malignancies, and to be made available to every child and young adult with cancer in Australia, by 2023. ZERO has improved outcomes for children with high-risk cancers and has transformed the approach of managing high-risk childhood cancers nationally.

Michelle is currently continuing work on identifying and validating the clinical role of molecular targets responsible for treatment failure in aggressive childhood cancers, with the overall goal of improving clinical outcomes for children with cancer.

Publications related to this Person

Book Chapters

Journal articles

Segura MF; Soriano A; Roma J; Piskareva O; Jiménez C; Boloix A; Fletcher JI; Haber M; Gray JC; Cerdá-Alberich L; Martínez de Las Heras B; Cañete A; Gallego S; Moreno L, 2022, 'Methodological advances in the discovery of novel neuroblastoma therapeutics', Expert Opinion on Drug Discovery, vol. 17, pp. 167 - 179, http://dx.doi.org/10.1080/17460441.2022.2002297

Hanssen KM; Wheatley MS; Yu DMT; Conseil G; Norris MD; Haber M; Cole SPC; Fletcher JI, 2022, 'GSH facilitates the binding and inhibitory activity of novel multidrug resistance protein 1 (MRP1) modulators', FEBS Journal, http://dx.doi.org/10.1111/febs.16374

Hu W; Zhao W; Kumar A; Singh GJ; Qi S; Casan J; Shembery C; Fong D; Zerbato JM; Symons J; Rudraraju R; Purcell D; Haber M; Voskoboinik I; Ekert PG; Lewin S; Trapani J; Fareh M, 2022, 'De novo design of CRISPR-Cas13b enables efficient silencing of SARS-CoV-2 variants and tumour pathogenic RNAs with near single-base precision', Pathology, vol. 54, pp. S15 - S16, http://dx.doi.org/10.1016/j.pathol.2021.12.057

Khan A; Gamble LD; Upton DH; Ung C; Yu DMT; Ehteda A; Pandher R; Mayoh C; Hébert S; Jabado N; Kleinman CL; Burns MR; Norris MD; Haber M; Tsoli M; Ziegler DS, 2021, 'Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas', Nature Communications, vol. 12, pp. 971, http://dx.doi.org/10.1038/s41467-021-20896-z

Fleuren EDG; Terry RL; Meyran D; Omer N; Trapani JA; Haber M; Neeson PJ; Ekert PG, 2021, 'Enhancing the potential of immunotherapy in paediatric sarcomas: Breaking the immunosuppressive barrier with receptor tyrosine kinase inhibitors', Biomedicines, vol. 9, pp. 1798 - 1798, http://dx.doi.org/10.3390/biomedicines9121798

Hanssen KM; Haber M; Fletcher JI, 2021, 'Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition', Drug Resistance Updates, vol. 59, pp. 100795 - 100795, http://dx.doi.org/10.1016/j.drup.2021.100795

Bӧhm JW; Sia KCS; Jones C; Evans K; Mariana A; Pang I; Failes T; Zhong L; Mayoh C; Landman R; Collins R; Erickson SW; Arndt G; Raftery MJ; Wilkins MR; Norris MD; Haber M; Marshall GM; Lock RB, 2021, 'Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia', Leukemia, vol. 35, pp. 3101 - 3112, http://dx.doi.org/10.1038/s41375-021-01248-8

Meyran D; Terry RL; Zhu JJ; Haber M; Ziegler DS; Ekert PG; Trapani JA; Darcy PK; Neeson PJ, 2021, 'Early-phenotype CAR-T cells for the treatment of pediatric cancers', Annals of Oncology, vol. 32, pp. 1366 - 1380, http://dx.doi.org/10.1016/j.annonc.2021.07.018

Gifford AJ; Murray J; Fletcher JI; Marshall GM; Norris MD; Haber M, 2021, 'A Primer for Assessing the Pathology in Mouse Models of Neuroblastoma', Current Protocols, vol. 1, pp. e310, http://dx.doi.org/10.1002/cpz1.310

Terry RL; Meyran D; Fleuren EDG; Mayoh C; Zhu J; Omer N; Ziegler DS; Haber M; Darcy PK; Trapani JA; Neeson PJ; Ekert PG, 2021, 'Chimeric antigen receptor t cell therapy and the immunosuppressive tumor microenvironment in pediatric sarcoma', Cancers, vol. 13, pp. 4704 - 4704, http://dx.doi.org/10.3390/cancers13184704

Xiao L; Somers K; Murray J; Pandher R; Karsa M; Ronca E; Bongers A; Terry R; Ehteda A; Gamble LD; Issaeva N; Leonova KI; O’Connor A; Mayoh C; Venkat P; Quek H; Brand J; Kusuma FK; Pettitt JA; Mosmann E; Kearns A; Eden G; Alfred S; Allan S; Zhai L; Kamili A; Gifford AJ; Carter DR; Henderson MJ; Fletcher JI; Marshall G; Johnstone RW; Cesare AJ; Ziegler DS; Gudkov AV; Gurova KV; Norris MD; Haber M, 2021, 'Dual targeting of chromatin stability by the curaxin CBL0137 and histone deacetylase inhibitor panobinostat shows significant preclinical efficacy in neuroblastoma', Clinical Cancer Research, vol. 27, pp. 4338 - 4352, http://dx.doi.org/10.1158/1078-0432.CCR-20-2357

Karsa M; Kosciolek A; Bongers A; Mariana A; Failes T; Gifford AJ; Kees UR; Cheung LC; Kotecha RS; Arndt GM; Haber M; Norris MD; Sutton R; Lock RB; Henderson MJ; Somers K, 2021, 'Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin', British Journal of Cancer, vol. 125, pp. 55 - 64, http://dx.doi.org/10.1038/s41416-021-01332-x

Xiao L; Yeung H; Haber M; Norris MD; Somers K, 2021, 'Immunometabolism: A ‘Hot’ Switch for ‘Cold’ Pediatric Solid Tumors', Trends in Cancer, vol. 7, pp. 751 - 777, http://dx.doi.org/10.1016/j.trecan.2021.05.002

Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Joshi S; Rouaen JRC; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Tolhurst O; Kankean A; Hayden E; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov AV; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS, 2021, 'Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG', Cell Reports, vol. 35, pp. 108994 - 108994, http://dx.doi.org/10.1016/j.celrep.2021.108994

Gamble LD; Purgato S; Henderson MJ; Di Giacomo S; Russell AJ; Pigini P; Murray J; Valli E; Milazzo G; Giorgi FM; Cowley M; Ashton LJ; Bhalshankar J; Schleiermacher G; Rihani A; Van Maerken T; Vandesompele J; Speleman F; Versteeg R; Koster J; Eggert A; Noguera R; Stallings RL; Tonini GP; Fong K; Vaksman Z; Diskin SJ; Maris JM; London WB; Marshall GM; Ziegler DS; Hogarty MD; Perini G; Norris MD; Haber M, 2021, 'A g316a polymorphism in the ornithine decarboxylase gene promoter modulates mycn‐driven childhood neuroblastoma', Cancers, vol. 13, http://dx.doi.org/10.3390/cancers13081807

Putra V; Hulme AJ; Tee AE; Sun JQJ; Atmadibrata B; Ho N; Chen J; Gao J; Norris MD; Haber M; Kavallaris M; Henderson MJ; McCarroll J; Trahair T; Liu T; Liu PY, 2021, 'The RNA-helicase DDX21 upregulates CEP55 expression and promotes neuroblastoma', Molecular Oncology, vol. 15, pp. 1162 - 1179, http://dx.doi.org/10.1002/1878-0261.12906

Cheung BB; Kleynhans A; Mittra R; Kim PY; Holien JK; Nagy Z; Ciampa OC; Seneviratne JA; Mayoh C; Raipuria M; Gadde S; Massudi H; Wong IPL; Tan O; Gong A; Suryano A; Diakiw SM; Liu B; Arndt GM; Liu T; Kumar N; Sangfelt O; Zhu S; Norris MD; Haber M; Carter DR; Parker MW; Marshall GM, 2021, 'A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma', Oncogene, vol. 40, pp. 2367 - 2381, http://dx.doi.org/10.1038/s41388-021-01712-w

Chen J; Nelson C; Wong M; Tee AE; Liu PY; La T; Fletcher JI; Kamili A; Mayoh C; Bartenhagen C; Trahair TN; Xu N; Jayatilleke N; Wong M; Peng H; Atmadibrata B; Cheung BB; Lan Q; Bryan TM; Mestdagh P; Vandesompele J; Combaret V; Boeva V; Wang JY; Janoueix-Lerosey I; Cowley MJ; MacKenzie KL; Dolnikov A; Li J; Polly P; Marshall GM; Reddel RR; Norris MD; Haber M; Fischer M; Zhang XD; Pickett HA; Liu T, 2021, 'Targeted therapy of TERT-rearranged neuroblastoma with BET bromodomain inhibitor and proteasome inhibitor combination therapy', Clinical Cancer Research, vol. 27, pp. 1438 - 1451, http://dx.doi.org/10.1158/1078-0432.CCR-20-3044

Grohmann C; Walker F; Devlin M; Luo MX; Chüeh AC; Doherty J; Vaillant F; Ho GY; Wakefield MJ; Weeden CE; Kamili A; Murray J; Po’uha ST; Weinstock J; Kane SR; Faux MC; Broekhuizen E; Zheng Y; Shield-Artin K; Kershaw NJ; Tan CW; Witchard HM; Ebert G; Charman SA; Street I; Kavallaris M; Haber M; Fletcher JI; Asselin-Labat ML; Scott CL; Visvader JE; Lindeman GJ; Watson KG; Burgess AW; Lessene G, 2021, 'Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors', Cell Death and Disease, vol. 12, http://dx.doi.org/10.1038/s41419-020-03269-0

Xu N; Tse B; Yang L; Tang TC; Haber M; Micklethwaite K; Dolnikov A, 2021, 'Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy', IMMUNOTARGETS AND THERAPY, vol. 10, pp. 123 - 140, http://dx.doi.org/10.2147/ITT.S296161

Xie J; Kumar A; Dolman MEM; Mayoh C; Khuong-Quang DA; Cadiz R; Wong-Erasmus M; Mould EVA; Grebert-Wade D; Barahona P; Kamili A; Tsoli M; Failes TW; Chow SO; Bhatia K; Marshall GM; Ziegler DS; Haber M; Lock RB; Tyrrell V; Lau L; Athanasatos P; Gifford AJ, 2021, 'The important role of routine cytopathology in pediatric precision oncology', Cancer Cytopathology, http://dx.doi.org/10.1002/cncy.22448

Subhash VV; Huang L; Kamili A; Wong M; Chen D; Venn NC; Atkinson C; Mayoh C; Venkat P; Tyrrell V; Marshall GM; Cowley MJ; Ekert PG; Norris MD; Haber M; Henderson MJ; Sutton R; Fletcher JI; Trahair TN, 2021, 'Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma', British Journal of Cancer, http://dx.doi.org/10.1038/s41416-021-01538-z

Sia KCS; Zhong L; Mayoh C; Norris MD; Haber M; Marshall GM; Raftery MJ; Lock RB, 2020, 'Targeting TSLP-induced tyrosine kinase signaling pathways in CRLF2-Rearranged Ph-like ALL', Molecular Cancer Research, vol. 18, pp. 1767 - 1776, http://dx.doi.org/10.1158/1541-7786.MCR-19-1098

Khuong-Quang DA; Brown LM; Wong M; Mayoh C; Sexton-Oates A; Kumar A; Pinese M; Nagabushan S; Lau L; Ludlow LE; Gifford AJ; Rodriguez M; Desai J; Fox SB; Haber M; Ziegler DS; Hansford JR; Marshall GM; Cowley MJ; Ekert PG, 2020, 'Recurrent SPECC1L–NTRK fusions in pediatric sarcoma and brain tumors', Cold Spring Harbor Molecular Case Studies, vol. 6, http://dx.doi.org/10.1101/MCS.A005710

Wong M; Mayoh C; Lau LMS; Khuong-Quang DA; Pinese M; Kumar A; Barahona P; Wilkie EE; Sullivan P; Bowen-James R; Syed M; Martincorena I; Abascal F; Sherstyuk A; Bolanos NA; Baber J; Priestley P; Dolman MEM; Fleuren EDG; Gauthier ME; Mould EVA; Gayevskiy V; Gifford AJ; Grebert-Wade D; Strong PA; Manouvrier E; Warby M; Thomas DM; Kirk J; Tucker K; O’Brien T; Alvaro F; McCowage GB; Dalla-Pozza L; Gottardo NG; Tapp H; Wood P; Khaw SL; Hansford JR; Moore AS; Norris MD; Trahair TN; Lock RB; Tyrrell V; Haber M; Marshall GM; Ziegler DS; Ekert PG; Cowley MJ, 2020, 'Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer', Nature Medicine, vol. 26, pp. 1742 - 1753, http://dx.doi.org/10.1038/s41591-020-1072-4

Ferrucci F; Ciaccio R; Monticelli S; Pigini P; Di Giacomo S; Purgato S; Erriquez D; Bernardoni R; Norris MD; Haber M; Milazzo G; Perini G, 2020, 'Corrigendum to: “MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma” [Biochim. Biophys. Acta, Gene Regul. Mech. 1861 (2018) 235–245] (BBA - Gene Regulatory Mechanisms (2018) 1861(3) (235–245), (S1874939917302894), (10.1016/j.bbagrm.2018.01.007))', Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, vol. 1863, http://dx.doi.org/10.1016/j.bbagrm.2020.194645

Jung M; Gao J; Cheung L; Bongers A; Somers K; Clifton M; Ramsay EE; Russell AJ; Valli E; Gifford AJ; George J; Kennedy CJ; Wakefield MJ; Topp M; Ho GY; Scott CL; Bowtell DD; deFazio A; Norris MD; Haber M; Henderson MJ, 2020, 'ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer', International Journal of Cancer, vol. 147, pp. 2225 - 2238, http://dx.doi.org/10.1002/ijc.33005

Hawkins C; Pfister S; Jones DTW; Shah NN; Gilbertson RJ; Sweet-Cordero EA; Dyer MA; Mossé YP; Haber M; DuBois SG, 2020, 'Advances and Challenges in Pediatric and Childhood Cancers', Cancer Cell, vol. 38, pp. 429 - 432, http://dx.doi.org/10.1016/j.ccell.2020.09.013

Voli F; Valli E; Lerra L; Kimpton K; Saletta F; Giorgi FM; Mercatelli D; Rouaen JRC; Shen S; Murray JE; Ahmed-Cox A; Cirillo G; Mayoh C; Beavis PA; Haber M; Trapani JA; Kavallaris M; Vittorio O, 2020, 'Intratumoral copper modulates PD-L1 expression and influences tumor immune evasion', Cancer Research, vol. 80, pp. 4129 - 4144, http://dx.doi.org/10.1158/0008-5472.CAN-20-0471

Gao J; Jung MS; Mayoh C; Venkat P; Hannan KM; Fletcher JI; Kamili A; Gifford AJ; Kusnadi EP; Pearson RB; Hannan RD; Haber M; Norris MD; Somers K; Henderson MJ, 2020, 'Suppression of ABCE1-mediated mRNA translation limits N-MYC-driven cancer progression', Cancer Research, vol. 80, pp. 3706 - 3718, http://dx.doi.org/10.1158/0008-5472.CAN-19-3914

Salik B; Yi H; Hassan N; Santiappillai N; Vick B; Connerty P; Duly A; Trahair T; Woo AJ; Beck D; Liu T; Spiekermann K; Jeremias I; Wang J; Kavallaris M; Haber M; Norris MD; Liebermann DA; D'Andrea RJ; Murriel C; Wang JY, 2020, 'Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia', Cancer Cell, vol. 38, pp. 263 - 278.e6, http://dx.doi.org/10.1016/j.ccell.2020.05.014

Korotchkina L; Kazyulkin D; Komarov PG; Polinsky A; Andrianova EL; Joshi S; Gupta M; Vujcic S; Kononov E; Toshkov I; Tian Y; Krasnov P; Chernov MV; Veith J; Antoch MP; Middlemiss S; Somers K; Lock RB; Norris MD; Henderson MJ; Haber M; Chernova OB; Gudkov AV, 2020, 'OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis', Leukemia, vol. 34, pp. 1828 - 1839, http://dx.doi.org/10.1038/s41375-019-0692-5

Terry RL; Meyran D; Ziegler DS; Haber M; Ekert PG; Trapani JA; Neeson PJ, 2020, 'Immune profiling of pediatric solid tumors', Journal of Clinical Investigation, vol. 130, pp. 3391 - 3402, http://dx.doi.org/10.1172/JCI137181

Somers K; Evans K; Cheung L; Karsa M; Pritchard T; Kosciolek A; Bongers A; El-Ayoubi A; Forgham H; Middlemiss S; Mayoh C; Jones L; Gupta M; Kees UR; Chernova O; Korotchkina L; Gudkov AV; Erickson SW; Teicher B; Smith MA; Norris MD; Haber M; Lock RB; Henderson MJ, 2020, 'Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia', Leukemia, vol. 34, pp. 1524 - 1539, http://dx.doi.org/10.1038/s41375-019-0683-6

Khan A; Valli E; Lam H; Scott DA; Murray J; Hanssen KM; Eden G; Gamble LD; Pandher R; Flemming CL; Allan S; Osterman AL; Haber M; Norris MD; Fletcher JI; Yu DMT, 2020, 'Targeting metabolic activity in high-risk neuroblastoma through Monocarboxylate Transporter 1 (MCT1) inhibition', Oncogene, vol. 39, pp. 3555 - 3570, http://dx.doi.org/10.1038/s41388-020-1235-2

Xie J; Span M; van Maarseveen E; Langenhorst J; Boddy AV; Sia KCS; Sutton R; Venn N; Punt AM; Tyrrell V; Haber M; Trahair T; Lau L; Marshall GM; Lock RB, 2020, 'Optimization of a clofarabine-based drug combination regimen for the preclinical evaluation of pediatric acute lymphoblastic leukemia', Pediatric Blood and Cancer, vol. 67, pp. e28133, http://dx.doi.org/10.1002/pbc.28133

Huynh T; Murray J; Flemming CL; Kamili A; Hofmann U; Cheung L; Roundhill EA; Yu DMT; Webber HT; Schwab M; Henderson MJ; Haber M; Norris MD; Fletcher JI, 2020, 'CCI52 sensitizes tumors to 6-mercaptopurine and inhibits MYCN-amplified tumor growth', Biochemical Pharmacology, vol. 172, http://dx.doi.org/10.1016/j.bcp.2019.113770

Kamili A; Gifford AJ; Li N; Mayoh C; Chow S-O; Failes TW; Eden GL; Cadiz R; Xie J; Lukeis RE; Norris MD; Haber M; McCowage GB; Arndt GM; Trahair TN; Fletcher JI, 2020, 'Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy', British Journal of Cancer, http://dx.doi.org/10.1038/s41416-019-0682-4

Wong M; Sun Y; Xi Z; Milazzo G; Poulos RC; Bartenhagen C; Bell JL; Mayoh C; Ho N; Tee AE; Chen X; Li Y; Ciaccio R; Liu PY; Jiang CC; Lan Q; Jayatilleke N; Cheung BB; Haber M; Norris MD; Zhang XD; Marshall GM; Wang JY; Hüttelmaier S; Fischer M; Wong JWH; Xu H; Perini G; Dong Q; George RE; Liu T, 2019, 'JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma', Nature Communications, vol. 10, pp. 3319, http://dx.doi.org/10.1038/s41467-019-11132-w

Liu PY; Tee AE; Milazzo G; Hannan KM; Maag J; Mondal S; Atmadibrata B; Bartonicek N; Peng H; Ho N; Mayoh C; Ciaccio R; Sun Y; Henderson MJ; Gao J; Everaert C; Hulme AJ; Wong M; Lan Q; Cheung BB; Shi L; Wang JY; Simon T; Fischer M; Zhang XD; Marshall GM; Norris MD; Haber M; Vandesompele J; Li J; Mestdagh P; Hannan RD; Dinger ME; Perini G; Liu T, 2019, 'The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35', Nature Communications, vol. 10, pp. 5026, http://dx.doi.org/10.1038/s41467-019-12971-3

Rokita JL; Rathi KS; Cardenas MF; Upton KA; Jayaseelan J; Cross KL; Pfeil J; Egolf LE; Way GP; Farrel A; Kendsersky NM; Patel K; Gaonkar KS; Modi A; Berko ER; Lopez G; Vaksman Z; Mayoh C; Nance J; McCoy K; Haber M; Evans K; McCalmont H; Bendak K; Böhm JW; Marshall GM; Tyrrell V; Kalletla K; Braun FK; Qi L; Du Y; Zhang H; Lindsay HB; Zhao S; Shu J; Baxter P; Morton C; Kurmashev D; Zheng S; Chen Y; Bowen J; Bryan AC; Leraas KM; Coppens SE; Doddapaneni HV; Momin Z; Zhang W; Sacks GI; Hart LS; Krytska K; Mosse YP; Gatto GJ; Sanchez Y; Greene CS; Diskin SJ; Vaske OM; Haussler D; Gastier-Foster JM; Kolb EA; Gorlick R; Li XN; Reynolds CP; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB; Raman P; Wheeler DA; Maris JM, 2019, 'Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design', Cell Reports, vol. 29, pp. 1675 - 1689.e9, http://dx.doi.org/10.1016/j.celrep.2019.09.071

Koach J; Holien JK; Massudi H; Carter DR; Ciampa OC; Herath M; Lim T; Seneviratne JA; Milazzo G; Murray JE; McCarroll JA; Liu B; Mayoh C; Keenan B; Stevenson BW; Gorman MA; Bell JL; Doughty L; Hüttelmaier S; Oberthuer A; Fischer M; Gifford AJ; Liu T; Zhang X; Zhu S; Gustafson WC; Haber M; Norris MD; Fletcher JI; Perini G; Parker MW; Cheung BB; Marshall GM, 2019, 'Drugging MYCN oncogenic signaling through the MYCN-PA2G4 binding interface', Cancer Research, vol. 79, pp. 5652 - 5667, http://dx.doi.org/10.1158/0008-5472.CAN-19-1112

Gana CC; Hanssen KM; Yu DMT; Flemming CL; Wheatley MS; Conseil G; Cole SPC; Norris MD; Haber M; Fletcher JI, 2019, 'MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells', Biochemical Pharmacology, vol. 168, pp. 237 - 248, http://dx.doi.org/10.1016/j.bcp.2019.07.009

Jones DTW; Banito A; Grünewald TGP; Haber M; Jäger N; Kool M; Milde T; Molenaar JJ; Nabbi A; Pugh TJ; Schleiermacher G; Smith MA; Westermann F; Pfister SM, 2019, 'Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours', Nature Reviews Cancer, vol. 19, pp. 420 - 438, http://dx.doi.org/10.1038/s41568-019-0169-x

Gonzales-Aloy E; Connerty P; Salik B; Liu B; Woo AJ; Haber M; Norris MD; Wang J; Wang JY, 2019, 'MiR-101 suppresses the development of MLL-rearranged acute myeloid leukemia', Haematologica, vol. 104, pp. e296 - e299, http://dx.doi.org/10.3324/haematol.2018.209437

Lynch JR; Salik B; Connerty P; Vick B; Leung H; Pijning A; Jeremias I; Spiekermann K; Trahair T; Liu T; Haber M; Norris MD; Woo AJ; Hogg P; Wang J; Wang JY, 2019, 'JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis', Leukemia, vol. 33, pp. 1400 - 1410, http://dx.doi.org/10.1038/s41375-018-0354-z

Somers K; Wen VW; Middlemiss SMC; Osborne B; Forgham H; Jung MS; Karsa M; Clifton M; Bongers A; Gao J; Mayoh C; Raoufi-Rad N; Kusnadi EP; Hannan KM; Scott DA; Kwek A; Liu B; Flemming C; Chudakova DA; Pandher R; Failes TW; Lim J; Angeli A; Osterman AL; Imamura T; Kees UR; Supuran CT; Pearson RB; Hannan RD; Davis TP; McCarroll J; Kavallaris M; Turner N; Gudkov AV; Haber M; Norris MD; Henderson MJ, 2019, 'A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction', Oncogene, vol. 38, pp. 3824 - 3842, http://dx.doi.org/10.1038/s41388-018-0666-5

Fultang L; Gamble LD; Gneo L; Berry AM; Egan SA; De Bie F; Yogev O; Eden GL; Booth S; Brownhill S; Vardon A; McConville CM; Cheng PN; Norris MD; Etchevers HC; Murray J; Ziegler DS; Chesler L; Schmidt R; Burchill SA; Haber M; De Santo C; Mussai F, 2019, 'Macrophage-derived IL1B and TNFa regulate arginine metabolism in neuroblastoma', Cancer Research, vol. 79, pp. 611 - 624, http://dx.doi.org/10.1158/0008-5472.CAN-18-2139

Dorstyn L; Hackett-Jones E; Nikolic A; Norris MD; Lim Y; Toubia J; Haber M; Kumar S, 2019, 'Transcriptome profiling of caspase-2 deficient EμMyc and Th-MYCN mouse tumors identifies distinct putative roles for caspase-2 in neuronal differentiation and immune signaling', Cell Death and Disease, vol. 10, http://dx.doi.org/10.1038/s41419-018-1296-0

Gamble LD; Purgato S; Murray J; Xiao L; Yu DMT; Hanssen KM; Giorgi FM; Carter DR; Gifford AJ; Valli E; Milazzo G; Kamili A; Mayoh C; Liu B; Eden G; Sarraf S; Allan S; Giacomo SD; Flemming CL; Russell AJ; Cheung BB; Oberthuer A; London WB; Fischer M; Trahair TN; Fletcher JI; Marshall GM; Ziegler DS; Hogarty MD; Burns MR; Perini G; Norris MD; Haber M, 2019, 'Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma', Science Translational Medicine, vol. 11, http://dx.doi.org/10.1126/scitranslmed.aau1099

Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ, 2019, 'Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia', International Journal of Cancer, http://dx.doi.org/10.1002/ijc.32582

Tsoli M; Wadham C; Pinese M; Failes T; Joshi S; Mould E; Yin JX; Gayevskiy V; Kumar A; Kaplan W; Ekert PG; Saletta F; Franshaw L; Liu J; Gifford A; Weber MA; Rodriguez M; Cohn RJ; Arndt G; Tyrrell V; Haber M; Trahair T; Marshall GM; McDonald K; Cowley MJ; Ziegler DS, 2018, 'Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer', Cancer Biology and Therapy, vol. 19, pp. 1078 - 1087, http://dx.doi.org/10.1080/15384047.2018.1491498

Jung M; Russell A; Kennedy C; Gifford A, 2018, 'Clinical Importance of Myc Family Oncogene Aberrations in Epithelial Ovarian Cancer', JNCI: Cancer Spectrum, vol. 2, http://dx.doi.org/10.1093/jncics/pky047

Ziegler DS; Wong M; Mayoh C; Kumar A; Tsoli M; Mould E; Tyrrell V; Khuong-Quang DA; Pinese M; Gayevskiy V; Cohn RJ; Lau LMS; Reynolds M; Cox MC; Gifford A; Rodriguez M; Cowley MJ; Ekert PG; Marshall GM; Haber M, 2018, 'Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma', British Journal of Cancer, vol. 119, pp. 693 - 696, http://dx.doi.org/10.1038/s41416-018-0251-2

Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT; Norris MD; Haber M; Liu T; De Preter K; Speleman F; Cheung BB; Marshall GM, 2018, 'Network modeling of microRNA-mRNA interactions in neuroblastoma tumorigenesis identifies miR-204 as a direct inhibitor of MYCN', Cancer Research, vol. 78, pp. 3122 - 3134, http://dx.doi.org/10.1158/0008-5472.CAN-17-3034

Fletcher JI; Ziegler DS; Trahair TN; Marshall GM; Haber M; Norris MD, 2018, 'Too many targets, not enough patients: Rethinking neuroblastoma clinical trials', Nature Reviews Cancer, vol. 18, pp. 389 - 400, http://dx.doi.org/10.1038/s41568-018-0003-x

Marachelian A; Hogarty MD; Flynn A; Liu K; Gerner EW; Bruckheimer E; Shamirian A; Hasenauer C; Norris M; Haber M; Groshen SG; Ziegler DS; Matthay KK, 2018, 'NANT 2012-01: Phase 1 study of DFMO and celecoxib with cyclophosphamide and topotecan for relapsed or refractory high-risk neuroblastoma.', JOURNAL OF CLINICAL ONCOLOGY, vol. 36, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.10558

Ferrucci F; Ciaccio R; Monticelli S; Pigini P; di Giacomo S; Purgato S; Erriquez D; Bernardoni R; Norris M; Haber M; Milazzo G; Perini G, 2018, 'MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma', Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, vol. 1861, pp. 235 - 245, http://dx.doi.org/10.1016/j.bbagrm.2018.01.007

Sutton R; Venn NC; Law T; Boer JM; Trahair TN; Ng A; Den Boer ML; Dissanayake A; Giles JE; Dalzell P; Mayoh C; Barbaric D; Revesz T; Alvaro F; Pieters R; Haber M; Norris MD; Schrappe M; Dalla Pozza L; Marshall GM, 2018, 'A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children', British Journal of Haematology, vol. 180, pp. 550 - 562, http://dx.doi.org/10.1111/bjh.15056

Somers K; Evans K; Cheung L; Korotchkina L; Chernova O; Gudkov A; Norris M; Haber M; Lock R; Henderson M, 2018, 'PO-028 Effective targeting of NAD+biosynthesis in patient-derived xenograft models of high-risk paediatric acute lymphoblastic leukaemia', ESMO Open, vol. 3, pp. A238 - A238, http://dx.doi.org/10.1136/esmoopen-2018-eacr25.563

Murray J; Valli E; Yu DMT; Truong AM; Gifford AJ; Eden GL; Gamble LD; Hanssen KM; Flemming CL; Tan A; Tivnan A; Allan S; Saletta F; Cheung L; Ruhle M; Schuetz JD; Henderson MJ; Byrne JA; Norris MD; Haber M; Fletcher JI, 2017, 'Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo', European Journal of Cancer, vol. 83, pp. 132 - 141, http://dx.doi.org/10.1016/j.ejca.2017.06.024

Dagg RA; Pickett HA; Neumann AA; Napier CE; Henson JD; Teber ET; Arthur JW; Reynolds CP; Murray J; Haber M; Sobinoff AP; Lau LMS; Reddel RR, 2017, 'Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres', Cell Reports, vol. 19, pp. 2544 - 2556, http://dx.doi.org/10.1016/j.celrep.2017.05.087

Burchill SA; Beiske K; Shimada H; Ambros PF; Seeger R; Tytgat GAM; Brock PR; Haber M; Park JR; Berthold F, 2017, 'Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group', Cancer, vol. 123, pp. 1095 - 1105, http://dx.doi.org/10.1002/cncr.30380

Jung MS; Russell AJ; Liu B; George J; Liu PY; Liu T; DeFazio A; Bowtell DDL; Oberthuer A; London WB; Fletcher JI; Haber M; Norris MD; Henderson MJ, 2017, 'A Myc activity signature predicts poor clinical outcomes in Myc-associated cancers', Cancer Research, vol. 77, pp. 971 - 981, http://dx.doi.org/10.1158/0008-5472.CAN-15-2906

Evageliou NF; Haber M; Vu A; Laetsch TW; Murray J; Gamble LD; Cheng NC; Liu K; Reese M; Corrigan KA; Ziegler DS; Webber H; Hayes CS; Pawel B; Marshall GM; Zhao H; Gilmour SK; Norris MD; Hogarty MD, 2016, 'Polyamine antagonist therapies inhibit neuroblastoma initiation and progression', Clinical Cancer Research, vol. 22, pp. 4391 - 4404, http://dx.doi.org/10.1158/1078-0432.CCR-15-2539

Lynch JR; Yi H; Casolari DA; Voli F; Gonzales-Aloy E; Fung TK; Liu B; Brown A; Liu T; Haber M; Norris MD; Lewis ID; So CWE; D'Andrea RJ; Wang JY, 2016, 'Gaq signaling is required for the maintenance of MLL-AF9-induced acute myeloid leukemia', Leukemia, vol. 30, pp. 1745 - 1748, http://dx.doi.org/10.1038/leu.2016.24

O'Brien R; Tran SL; Maritz MF; Liu B; Kong CF; Purgato S; Yang C; Murray J; Russell AJ; Flemming CL; von Jonquieres G; Pickett HA; London WB; Haber M; Gunaratne PH; Norris MD; Perini G; Fletcher JI; MacKenzie KL, 2016, 'MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin', Cancer Research, vol. 76, pp. 3604 - 3617, http://dx.doi.org/10.1158/0008-5472.CAN-15-0879

Carter DR; Sutton SK; Pajic M; Murray J; Sekyere EO; Fletcher J; Beckers A; De Preter K; Speleman F; George RE; Haber M; Norris MD; Cheung BB; Marshall GM, 2016, 'Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis', Molecular Oncology, vol. 10, pp. 866 - 878, http://dx.doi.org/10.1016/j.molonc.2016.02.004

Kim PY; Tan O; Liu B; Trahair T; Liu T; Haber M; Norris MD; Marshall GM; Cheung BB, 2016, 'High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients', Cancer Letters, vol. 374, pp. 315 - 323, http://dx.doi.org/10.1016/j.canlet.2016.02.021

Fletcher JI; Williams RT; Henderson MJ; Norris MD; Haber M, 2016, 'ABC transporters as mediators of drug resistance and contributors to cancer cell biology', Drug Resistance Updates, vol. 26, pp. 1 - 9, http://dx.doi.org/10.1016/j.drup.2016.03.001

Decock A; Ongenaert M; Cannoodt R; Verniers K; Wilde BD; Laureys G; Van Roy N; Berbegall AP; Bienertova-Vasku J; Bown N; Clément N; Combaret V; Haber M; Hoyoux C; Murray J; Noguera R; Pierron G; Schleiermacher G; Schulte JH; Stallings RL; Tweddle DA; De Preter K; Speleman F; Vandesompele J, 2016, 'Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma', Oncotarget, vol. 7, pp. 1960 - 1972, http://dx.doi.org/10.18632/oncotarget.6477

French JD; Johnatty SE; Lu Y; Beesley J; Gao B; Kalimutho M; Henderson MJ; Russell AJ; Kar S; Chen X; Hillman KM; Kaufmann S; Sivakumaran H; O'Reilly M; Wang C; Korbie DJ; Lambrechts D; Despierre E; Van Nieuwenhuysen E; Lambrechts S; Vergote I; Karlan B; Lester J; Orsulic S; Walsh C; Fasching PA; Beckmann MW; Ekici AB; Hein A; Matsuo K; Hosono S; Pisterer J; Hillemanns P; Nakanishi T; Yatabe Y; Goodman MT; Lurie G; Matsuno RK; Thompson PJ; Pejovic T; Bean Y; Heitz F; Harter P; Du Bois A; Schwaab I; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Lundvall L; Engelholm SA; Brown B; Flanagan JM; Metcalf MD; Siddiqui N; Sellers T; Fridley B; Cunningham J; Schildkraut JM; Iversen E; Weber RP; Brennan D; Berchuck A; Pharoah P; Harnett P; Norris MD; Haber M; Goode EL; Lee JS; Khanna KK; Meyer KB; Chenevix-Trench G; DeFazio A; Edwards SL; MacGregor S, 2016, 'Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer', Oncotarget, vol. 7, pp. 6353 - 6368, http://dx.doi.org/10.18632/oncotarget.7047

Tee AE; Liu B; Song R; Li J; Pasquier E; Cheung BB; Jiang C; Marshall GM; Haber M; Norris MD; Fletcher JI; Dinger ME; Liu T, 2016, 'The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression', Oncotarget, vol. 7, pp. 8663 - 8675, http://dx.doi.org/10.18632/oncotarget.6675

Somers K; Chudakova DA; Middlemiss SMC; Wen VW; Clifton M; Kwek A; Liu B; Mayoh C; Bongers A; Karsa M; Pan S; Cruikshank S; Scandlyn M; Hoang W; Imamura T; Kees UR; Gudkov AV; Chernova OB; Haber M; Norris MD; Henderson MJ, 2016, 'CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements', Oncotarget, vol. 7, pp. 46067 - 46087, http://dx.doi.org/10.18632/oncotarget.10022

Vittorio O; Brandl M; Cirillo G; Kimpton K; Hinde E; Gaus K; Yee E; Kumar N; Duong H; Fleming C; Haber M; Norris M; Boyer C; Kavallaris M, 2016, 'Dextran-Catechin: An anticancer chemically-modified natural compound targeting copper that attenuates neuroblastoma growth', Oncotarget, vol. 7, pp. 47479 - 47493, http://dx.doi.org/10.18632/oncotarget.10201

Xue C; Yu DMT; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD, 2016, 'MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4', Oncotarget, vol. 7, pp. 54937 - 54951, http://dx.doi.org/10.18632/oncotarget.10709

Liu PY; Sokolowski N; Guo ST; Siddiqi F; Atmadibrata B; Telfer TJ; Sun Y; Zhang L; Yu D; Mccarroll J; Liu B; Yang RH; Guo XY; Tee AE; Itoh K; Wang J; Kavallaris M; Haber M; Norris MD; Cheung BB; Byrne JA; Ziegler DS; Marshall GM; Dinger ME; Codd R; Zhang XD; Liu T, 2016, 'The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs', Oncotarget, vol. 7, pp. 79217 - 79232, http://dx.doi.org/10.18632/oncotarget.12640

Koach J; Murray JE; McCarroll J; Milazzo G; Perini G; Haber M; Norris MD; Fletcher JI; Cheung BB; Marshall GM, 2016, 'Proffered Paper: Targeting PA2G4, a novel MYCN co-factor, for the treatment of neuroblastoma', European Journal of Cancer, vol. 61, pp. S7 - S7, http://dx.doi.org/10.1016/s0959-8049(16)61016-x

Carter DR; Murray J; Cheung BB; Gamble L; Koach J; Tsang J; Sutton S; Kalla H; Syed S; Gifford AJ; Issaeva N; Biktasova A; Atmadibrata B; Sun Y; Sokolowski N; Ling D; Kim PY; Webber H; Clark A; Ruhle M; Liu B; Oberthuer A; Fischer M; Byrne J; Saletta F; Thwe LM; Purmal A; Haderski G; Burkhart C; Speleman F; De Preter K; Beckers A; Ziegler DS; Liu T; Gurova KV; Gudkov AV; Norris MD; Haber M; Marshall GM, 2015, 'Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma', Science Translational Medicine, vol. 7, http://dx.doi.org/10.1126/scitranslmed.aab1803

Cheung BB; Tan O; Koach J; Liu B; Shum MSY; Carter DR; Sutton S; Po'uha ST; Chesler L; Haber M; Norris MD; Kavallaris M; Liu T; O'Neill GM; Marshall GM, 2015, 'Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma', Molecular Oncology, vol. 9, pp. 1484 - 1500, http://dx.doi.org/10.1016/j.molonc.2015.04.005

Bassiri H; Benavides A; Haber M; Gilmour SK; Norris MD; Hogarty MD, 2015, 'Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma', TRANSLATIONAL PEDIATRICS, vol. 4, pp. 226 - 238, http://dx.doi.org/10.3978/j.issn.2224-4336.2015.04.06

Greenop KR; Scott RJ; Attia J; Bower C; De Klerk NH; Norris MD; Haber M; Jamieson SE; Van Bockxmeer FM; Gottardo NG; Ashton LJ; Armstrong BK; Milne E, 2015, 'Folate pathway gene polymorphisms and risk of childhood brain tumors: Results from an Australian case-control study', Cancer Epidemiology Biomarkers and Prevention, vol. 24, pp. 931 - 937, http://dx.doi.org/10.1158/1055-9965.EPI-14-1248

Sutton R; Shaw PJ; Venn NC; Law T; Dissanayake A; Kilo T; Haber M; Norris MD; Fraser C; Alvaro F; Revesz T; Trahair TN; Dalla-Pozza L; Marshall GM; O'Brien TA, 2015, 'Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia', British Journal of Haematology, vol. 168, pp. 395 - 404, http://dx.doi.org/10.1111/bjh.13142

Yu DMT; Huynh T; Truong AM; Haber M; Norris MD, 2015, 'ABC Transporters and Neuroblastoma', Advances in Cancer Research, vol. 125, pp. 139 - 170, http://dx.doi.org/10.1016/bs.acr.2014.10.005

Milne E; Greenop KR; Scott RJ; Haber M; Norris MD; Attia J; Jamieson SE; Miller M; Bower C; Bailey HD; Dawson S; McCowage GB; De Klerk NH; Van Bockxmeer FM; Armstrong BK, 2015, 'Folate pathway gene polymorphisms, maternal folic acid use, and risk of childhood acute lymphoblastic leukemia', Cancer Epidemiology Biomarkers and Prevention, vol. 24, pp. 48 - 56, http://dx.doi.org/10.1158/1055-9965.EPI-14-0680

Lau DT; Flemming CL; Gherardi S; Perini G; Oberthuer A; Fischer M; Juraeva D; Brors B; Xue C; Norris MD; Marshall GM; Haber M; Fletcher JI; Ashton LJ, 2015, 'MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma', Oncotarget, vol. 6, pp. 15510 - 15523, http://dx.doi.org/10.18632/oncotarget.3732

Dietrich PA; Yang C; Leung HHL; Lynch JR; Gonzales E; Liu B; Haber M; Norris MD; Wang J; Wang JY, 2014, 'GPR84 sustains aberrant β-catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesis', Blood, vol. 124, pp. 3284 - 3294, http://dx.doi.org/10.1182/blood-2013-10-532523

Saletta F; Wadham C; Byrne J; Ziegler D; McCowage G; Haber M; Marshal G; Norris M, 2014, 'Molecular profiling for factors predicting sensitivity or resistance to therapy in relapsed child cancer', EUROPEAN JOURNAL OF CANCER, vol. 50, pp. 135 - 135, http://dx.doi.org/10.1016/S0959-8049(14)70547-7

Cheung L; Flemming CL; Watt F; Masada N; Yu DMT; Huynh T; Conseil G; Tivnan A; Polinsky A; Gudkov AV; Munoz MA; Vishvanath A; Cooper DMF; Henderson MJ; Cole SPC; Fletcher JI; Haber M; Norris MD, 2014, 'High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4)', Biochemical Pharmacology, vol. 91, pp. 97 - 108, http://dx.doi.org/10.1016/j.bcp.2014.05.023

Hedditch EL; Gao B; Russell AJ; Lu Y; Emmanuel C; Beesley J; Johnatty SE; Chen X; Harnett P; George J; Williams RT; Flemming C; Lambrechts D; Despierre E; Lambrechts S; Vergote I; Karlan B; Lester J; Orsulic S; Walsh C; Fasching P; Beckmann MW; Ekici AB; Hein A; Matsuo K; Hosono S; Nakanishi T; Yatabe Y; Pejovic T; Bean Y; Heitz F; Harter P; Du Bois A; Schwaab I; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Lundvall L; Engelholm SA; Brown B; Flanagan J; Metcalf MD; Siddiqui N; Sellers T; Fridley B; Cunningham J; Schildkraut J; Iversen E; Weber RP; Berchuck A; Goode E; Bowtell DD; Chenevix-Trench G; Defazio A; Norris MD; Macgregor S; Haber M; Henderson MJ, 2014, 'ABCA transporter gene expression and poor outcome in epithelial ovarian cancer', Journal of the National Cancer Institute, vol. 106, http://dx.doi.org/10.1093/jnci/dju149

Gao B; Russell A; Beesley J; Chen XQ; Healey S; Henderson M; Wong M; Emmanuel C; Galletta L; Johnatty SE; Bowtell D; Haber M; Norris M; Harnett P; Chenevix-Trench G; Balleine RL; Defazio A; Gertig D; Green A; Webb P; Hung J; Moore S; Traficante N; Fereday S; Harrap K; Sadkowsky T; Pandeya N; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Pavlakis N; Valmadre S; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J; Dalrymple C; Hamilton A; Houghton R; Russell P; Links M; Grygiel J; Hill J; Brand A; Byth K; Jaworski R; Sharma R; Achen A; Wain G; Ward B; Papadimos D; Crandon A; Cummings M; Horwood K; Obermair A; Perrin L; Wyld D; Nicklin J; Davy M; Oehler MK; Hall C; Dodd T; Healy T; Pittman K; Henderson D; Miller J; Pierdes J; Blomfield P; Challis D; McIntosh R; Parker A; Brown B; Rome R; Allen D; Grant P; Hyde S; Laurie R; Robbie M; Healy D, 2014, 'Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer', Scientific Reports, vol. 4, http://dx.doi.org/10.1038/srep04669

Heong V; Topp M; Rutkowski R; Ananda S; Wong S; Swisher E; Lindeman G; Haber M; Norris MD; Haluska P; Wakefield M; Bowtell D; Scott CL; Lindeman G, 2014, 'USE OF NOVEL PATIENT-DERIVED XENOGRAFTS AND MOLECULAR SUBTYPING TO IMPROVE PRECISION MEDICINE IN HIGH-GRADE SEROUS OVARIAN CANCER', EUROPEAN JOURNAL OF CANCER, vol. 50, pp. E9 - E9, http://dx.doi.org/10.1016/j.ejca.2014.03.042

Tee EL; Ling D; Nelson C; Atmadibrata B; Dinger M; XU N; Mizukami T; Liu PY; Liu B; Cheung B; Pasquier E; Haber M; Norris MD; Suzuki T; Marshall GM; Liu T, 2014, 'The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1', Oncotarget, vol. 5, pp. 1793 - 1804, http://dx.doi.org/10.18632/oncotarget.1785

Kim PY; Tan O; Diakiw SM; Carter D; Sekerye EO; Wasinger VC; Liu T; Kavallaris M; Norris MD; Haber M; Chesler L; Dolnikov A; Trahair TN; Cheung NK; Marshall GM; Cheung BB, 2014, 'Identification of plasma Complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach', Journal of Proteomics, vol. 96, pp. 1 - 12, http://dx.doi.org/10.1016/j.jprot.2013.10.032

Saletta F; Wadham C; Ziegler DS; Marshall GM; Haber M; McCowage G; Norris MD; Byrne JA, 2014, 'Molecular profiling of childhood cancer: Biomarkers and novel therapies', BBA Clinical, vol. 1, pp. 59 - 77, http://dx.doi.org/10.1016/j.bbacli.2014.06.003

Shahbazi J; Scarlett CJ; Norris MD; Liu B; Haber M; Tee AE; Carrier A; Biankin AV; London WB; Marshall GM; Lock RB; Liu T, 2014, 'Histone Deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1', Oncotarget, vol. 5, pp. 4257 - 4268, http://dx.doi.org/10.18632/oncotarget.1991

Dorstyn L; Puccini J; Nikolic A; Shalini S; Wilson CH; Norris MD; Haber M; Kumar S, 2014, 'An unexpected role for caspase-2 in neuroblastoma', Cell Death and Disease, vol. 5, http://dx.doi.org/10.1038/cddis.2014.342

Karsa M; Dalla Pozza L; Venn NC; Law T; Shi R; Giles JE; Bahar AY; Cross S; Catchpoole D; Haber M; Marshall GM; Norris MD; Sutton R, 2013, 'Improving the Identification of High Risk Precursor B Acute Lymphoblastic Leukemia Patients with Earlier Quantification of Minimal Residual Disease', PLoS ONE, vol. 8, http://dx.doi.org/10.1371/journal.pone.0076455

Marshall GM; Dalla Pozza L; Sutton R; Ng A; De Groot-Kruseman HA; Van Der Velden VH; Venn NC; Van Den Berg H; De Bont ESJM; Maarten Egeler R; Hoogerbrugge PM; Kaspers GJL; Bierings MB; Van Der Schoot E; Van Dongen J; Law T; Cross S; Mueller H; De Haas V; Haber M; Révész T; Alvaro F; Suppiah R; Norris MD; Pieters R, 2013, 'High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation', Leukemia, vol. 27, pp. 1497 - 1503, http://dx.doi.org/10.1038/leu.2013.44

Johnatty SE; Beesley J; Gao B; Chen X; Lu Y; Law MH; Henderson MJ; Russell AJ; Hedditch EL; Emmanuel C; Fereday S; Webb PM; Goode EL; Vierkant RA; Fridley BL; Cunningham JM; Fasching PA; Beckmann MW; Ekici AB; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Brown R; Paul J; Lambrechts S; Despierre E; Vergote I; Lester J; Karlan BY; Heitz F; Du Bois A; Harter P; Schwaab I; Bean Y; Pejovic T; Levine DA; Goodman MT; Camey ME; Thompson PJ; Lurie G; Shildkraut J; Berchuck A; Terry KL; Cramer DW; Norris MD; Haber M; MacGregor S; DeFazio A; Chenevix-Trench G, 2013, 'ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and the Cancer Genome Atlas', Gynecologic Oncology, vol. 131, pp. 8 - 14, http://dx.doi.org/10.1016/j.ygyno.2013.07.107

Burkhart CA; Haber M; Norris MD; Gudkov AV; Nikiforov MA, 2013, 'Cell-based methods for the identification of Myc-inhibitory small molecules', Methods in Molecular Biology, vol. 1012, pp. 255 - 264, http://dx.doi.org/10.1007/978-1-62703-429-6_18

Liu PY; Xu N; Malyukova A; Scarlett CJ; Sun YT; Zhang XD; Ling D; Su SP; Nelson CA; Chang DK; Koach J; Tee AE; Haber M; Norris MD; Rooman I; Toon C; Xue C; Cheung B; Kumar S; Marshall GM; Biankin AV; Liu T, 2013, 'The histone deacetylase SIRT2 stabilizes Myc oncoproteins', Cell Death and Differentiation, vol. 20, pp. 503 - 514, http://dx.doi.org/10.1038/cdd.2012.147

Sekyere E; Thomas WD; Keating J; Calao M; Cui HJ; Chen JB; Raif A; Jankowski K; Cheung B; Davies NP NP; Trahair TN; Liu T; Wainwright BJ; Ding HF; Marshall GM, 2013, 'Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation', Oncogene, vol. 32, pp. 3616 - 3626, http://dx.doi.org/10.1038/onc.2012.368

Malyukova A; Papa R; O'Brien R; Giles JE; Trahair TN; Pozza LD; Sutton R; Liu T; Haber M; Norris MD; Lock RB; Marshall GM; Giles J, 2013, 'FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation', Leukemia, vol. 27, pp. 1053 - 1062, http://dx.doi.org/10.1038/leu.2012.361

Kim PY; Rahmanto AS; Tan O; Norris MD; Haber M; Marshall GM; Cheung BB, 2013, 'TRIM16 overexpression induces apoptosis through activation of caspase-2 in cancer cells', Apoptosis, vol. 18, pp. 639 - 651, http://dx.doi.org/10.1007/s10495-013-0813-y

Huynh T; Norris MD; Haber M; Henderson MJ, 2012, 'ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma', FRONTIERS IN ONCOLOGY, vol. 2, http://dx.doi.org/10.3389/fonc.2012.00178

Wang JY; Sprod O; Haber M; Norris MD, 2012, 'Epigenetic Elimination of Mixed-Lineage Leukemia Leukemic Stem Cells by a Potent Small Molecule PRC2 Inhibitor.', Blood, vol. 120, pp. 2456 - 2456, http://dx.doi.org/10.1182/blood.v120.21.2456.2456

Lau DT; Hesson LB; Norris MD; Haber M; Marshall GM; Ashton LJ, 2012, 'Prognostic significance of promoter DNA methylation in patients with neuroblastoma', CANCER RESEARCH, vol. 72, http://dx.doi.org/10.1158/1538-7445.AM2012-1425

Cheung BB; Koach J; Tan O; Kim P; Bell J; D'andreti C; Sutton S; Malyukova A; Sekyere E; Norris MD; Haber M; Kavallaris M; Cunningham AM; Proby C; Leigh I; Wilmott J; Cooper C; Halliday GM; Scolyer RA; Marshall GM, 2012, 'The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro', Journal of Pathology, vol. 226, pp. 451 - 462, http://dx.doi.org/10.1002/path.2986

Keating J; Tsoli M; Hallahan AR; Ingram WJ; Haber M; Ziegler DS, 2012, 'Targeting the inhibitor of apoptosis proteins as a novel therapeutic strategy in medulloblastoma', Molecular Cancer Therapeutics, vol. 11, pp. 2654 - 2663, http://dx.doi.org/10.1158/1535-7163.MCT-12-0352

Lau DT; Hesson L; Norris MD; Marshall GM; Haber M; Ashton LJ, 2012, 'Prognostic Significance of Promoter DNA Methylation in Patients with Childhood Neuroblastoma', Clinical Cancer Research, vol. 18, pp. 5690 - 5700, http://dx.doi.org/10.1158/1078-0432.CCR-12-0294

Schleiermacher G; Mosseri V; London WB; Maris JM; Brodeur GM; Attiyeh E; Haber M; Khan J; Nakagawara A; Speleman F; Noguera R; Tonini GP; Fischer M; Ambros I; Monclair T; Matthay KK; Ambros P; Cohn SL; Pearson ADJ, 2012, 'Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project', British Journal of Cancer, vol. 107, pp. 1418 - 1422, http://dx.doi.org/10.1038/bjc.2012.375

Fletcher JI; Gherardi S; Murray J; Burkhart C; Russell A; Valli E; Smith J; Oberthuer A; Ashton LJ; London WB; Marshall GM; Norris MD; Perini G; Haber M, 2012, 'N-Myc Regulates Expression of the Detoxifying Enzyme Glutathione Transferase GSTP1, a Marker of Poor Outcome in Neuroblastoma', Cancer Research, vol. 72, pp. 845 - 853, http://dx.doi.org/10.1158/0008-5472.CAN-11-1885

Venn NC; Van der velden VHJ; De bie M; Waanders E; Giles JE; Law T; Kuiper RP; de Haas V; Mullighan CG; Haber M; Marshall GM; Norris MD; Van dongen JJM; Sutton R; Giles J; Law T, 2012, 'Highly sensitive MRD tests for ALL based on the IKZF1 Delta 3-6 microdeletion', Leukemia, vol. 26, pp. 1414 - 1416, http://dx.doi.org/10.1038/leu.2011.348

Gamble LD; Hogarty MD; Liu X; Ziegler DS; Marshall GM; Norris MD; Haber M, 2012, 'Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma', Frontiers in Oncology, vol. 2, pp. 1 - 10, http://dx.doi.org/10.3389/fonc.2012.00162

Lau DT; Hesson LB; Norris MD; Marshall G; Haber M; Ashton LJ, 2012, 'Abstract 68: Beyond GWAS: The prognostic significance of promoter DNA methylation in patients with neuroblastoma.', Cancer Epidemiology Biomarkers & Prevention, vol. 21, pp. 68 - 68, http://dx.doi.org/10.1158/1055-9965.gwas-68

Chenevix-Trench G; Lu Y; Johnatty S; Gamazon E; Beesley J; Chen X; Gao B; Harnett P; Stephanie Huang R; Despierre E; Heitz F; Hogdall E; Hogdall C; Brown R; Moyisch K; Fasching P; Goode E; Russell A; Henderson M; Haber M; Dolan E; Macgregor S; deFazio A, 2012, 'Identification of a genetic variant associated with treatment outcome in ovarian cancer: the potential role of cholesterol metabolism as a determinant of response to chemotherapy', Hereditary Cancer in Clinical Practice, vol. 10, pp. A36 - A36, http://dx.doi.org/10.1186/1897-4287-10-s2-a36

Carpinteri S, 2012, 'Optimizing DNA Vaccines Against Nuclear Oncogenes', ImmunoGastroenterology, vol. 1, pp. 108 - 108, http://dx.doi.org/10.7178/ig.19

Bailey HD; Armstrong BK; de Klerk NH; Fritschi L; Attia J; Scott RJ; Smibert E; Milne E, 2011, 'Exposure to professional pest control treatments and the risk of childhood acute lymphoblastic leukemia', INTERNATIONAL JOURNAL OF CANCER, vol. 129, pp. 1678 - 1688, http://dx.doi.org/10.1002/ijc.25769

Bailey HD; Milne E; de Klerk NH; Fritschi L; Attia J; Cole C; Armstrong BK, 2011, 'Exposure to house painting and the use of floor treatments and the risk of childhood acute lymphoblastic leukemia', INTERNATIONAL JOURNAL OF CANCER, vol. 128, pp. 2405 - 2414, http://dx.doi.org/10.1002/ijc.25572

Milne E; Royle JA; Bennett LC; de Klerk NH; Bailey HD; Bower C; Miller M; Attia J; Scott RJ; Kirby M; Armstrong BK, 2011, 'Maternal consumption of coffee and tea during pregnancy and risk of childhood ALL: results from an Australian case-control study', CANCER CAUSES & CONTROL, vol. 22, pp. 207 - 218, http://dx.doi.org/10.1007/s10552-010-9688-1

Lau DTT; Norris MD; Marshall GM; Haber M; Ashton LJ, 2011, 'HLA-G polymorphisms, genetic susceptibility, and clinical outcome in chidlhood neuroblastoma', Tissue Antigens, vol. 78, pp. 421 - 427, http://dx.doi.org/10.1111/j.1399-0039.2011.01781.x

Marshall GM; Liu PY; Gherardi S; Scarlett CJ; Bedalov A; Xu N; Iraci N; Valli E; Ling D; Thomas W; Van bekkum M; Sekyere E; Jankowski K; Trahair T; Mackenzie K; Haber M; Norris MD; Biankin AV; Perini G; Liu T, 2011, 'SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability', PLOS Genetics, vol. 7, pp. e1 - e14, http://dx.doi.org/10.1371/journal.pgen.1002135

Pajic M; Murray JE; Marshall GM; Cole SPC; Norris MD; Haber M, 2011, 'ABCC1 G2012T single nucleotide polymorphism is associated with patient outcome in primary neuroblastoma and altered stability of the ABCC1 gene transcript', Pharmacogenetics and Genomics, vol. 21, pp. 270 - 279, http://dx.doi.org/10.1097/FPC.00b013e328343dd5f

Henderson M; Haber M; Porro A; Munoz M; Xue C; Murray JE; Flemming C; Smith J; Fletcher JI; Gherardi S; Kwek C; Russell AJ; Valli E; London WB; Buxton AB; Ashton LJ; Sartorelli AC; Cohn SL; Schwab M; Marshall GM; Perini G; Norris MD, 2011, 'ABCC Multidrug Transporters in Childhood Neuroblastoma: Clinical and Biological Effects Independent of Cytotoxic Drug Efflux', Journal of the National Cancer Institute, vol. 103, pp. 1236 - 1251, http://dx.doi.org/10.1093/jcni/djr256

Porro A; Iraci N; Soverini S; Diolaiti D; Gherardi S; Terragna C; Durante S; Valli E; Kalebic T; Bernardoni R; Perrod C; Haber M; Norris MD; Baccarani M; Martinelli G; Perini G, 2011, 'c-MYC Oncoprotein Dictates Transcriptional Profiles of ATP-Binding Cassette Transporter Genes in Chronic Myelogenous Leukemia CD34(+) Hematopoietic Progenitor Cells', Molecular Cancer Research, vol. 9, pp. 1054 - 1066, http://dx.doi.org/10.1158/1541-7786.MCR-10-0510

Swarbrick A; Woods SL; Shaw A; Balakrishnan A; Phua Y; Nguyen A; Chanthery Y; Lim L; Ashton LJ; Judson RL; Blelloch R; Huskey N; Haber M; Norris MD; Lengyel P; Hackett CS; Preiss T; Chetcuti A; Sullivan CS; Marcusson EG; Weiss W; L''Etoile N; Goga A, 2010, 'miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma', Nature Medicine, vol. 16, pp. 1134 - 1141, http://dx.doi.org/10.1038/nm.2227

Marshall GM; Gherardi S; Xu N; Neiron Z; Trahair TN; Scarlett CJ; Chang DK; Liu PY; Jankowski K; Iraci N; Haber M; Norris MD; Keating J; Sekyere E; Jonquieres G; Biankin AV; Stossi F; Katzenellenbogen BS; Perini G; Liu T, 2010, 'Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects', Oncogene, vol. 29, pp. 5957 - 5968, http://dx.doi.org/10.1038/onc.2010.332

Liu T, 2010, 'Opposing Effects of Two Tissue Transglutaminase Protein Isoforms in Neuroblastoma Cell Differentiation', The Journal of Biological Chemistry, vol. 285, pp. 3561 - 3567, http://dx.doi.org/10.1074/jbc.M109.053041

Liu T, 2010, 'TRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells', Oncogene, vol. 29, pp. 6172 - 6183, http://dx.doi.org/10.1038/onc.2010.340

Fletcher JI; Haber M; Henderson M; Norris MD, 2010, 'ABC transporters in cancer: more than just drug efflux pumps', Nature Reviews Cancer, vol. 10, pp. 147 - 156, http://dx.doi.org/10.1038/nrc2789

Porro A; Haber M; Diolaiti D; Iraci N; Henderson M; Gherardi S; Valli E; Munoz M; Xue C; Flemming C; Schwab M; Wong JH; Marshall GM; Della valle G; Norris MD; Perini G, 2010, 'Direct and Coordinate Regulation of ATP-binding Cassette Transporter Genes by Myc Factors Generates Specific Transcription Signatures That Significantly Affect the Chemoresistance Phenotype of Cancer Cells', The Journal of Biological Chemistry, vol. 285, pp. 19532 - 19543, http://dx.doi.org/10.1074/jbc.M109.078584

Milne E; Royle JA; Miller M; Bower C; de klerk NH; Bailey HD; Van brockxmeer F; Attia J; Scott RJ; Norris MD; Haber M; Thompson JR; Fritschi L; Marshall GM; Armstrong B, 2010, 'Maternal folate and other vitamin supplementation during pregnancy and risk of acute lymphoblastic leukemia in the offspring', International Journal of Cancer, vol. 126, pp. 2690 - 2699, http://dx.doi.org/10.1002/ijc.24969

Bhadri V; McGregor MR; Venn NC; Hackenberg N; Russell SJ; Norris MD; Haber M; Sutton R; Marshall GM, 2010, 'Isolated testicular relapse after allo-SCT in boys with ALL: outcome without second transplant', Bone Marrow Transplantation, vol. 45, pp. 397 - 399, http://dx.doi.org/10.1038/bmt.2009.138

Liu T, 2009, 'The cyclin-dependent kinase inhibitor, p21WAF1, promotes angiogenesis by repressing gene transcription of thioredoxin-binding protein 2 in cancer cells', Carcinogenesis, vol. 30, pp. 1865 - 1871, http://dx.doi.org/10.1093/carcin/bgp225

Liu T, 2009, 'Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors', European Journal of Cancer, vol. 45, pp. 1846 - 1854, http://dx.doi.org/10.1016/j.ejca.2009.03.002

Dilda P; Decollogne SM; Weerakoon L; Norris MD; Haber M; Allen JD; Hogg PJ, 2009, 'Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol', Journal of Medicinal Chemistry, vol. 52, pp. 6209 - 6216, http://dx.doi.org/10.1021/jm9008339

Brisco MJ; Latham S; Sutton R; Hughes E; Wilczek V; Van Zanten K; Budgen B; Malec M; Sykes PJ; Kuss BJ; Waters K; Venn NC; Giles J; Haber M; Norris MD; Marshall GM; Morley AA; Bahar ; Giles J, 2009, 'Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia', Journal of Molecular Diagnostics, vol. 11, pp. 194 - 200, http://dx.doi.org/10.2353/jmoldx.2009.080047

Burkhart CA; Watt F; Murray J; Pajic M; Prokvolit A; Xue C; Flemming C; Smith J; Purmal A; Isachenko N; Komarov PG; Gurova KV; Sartorelli AC; Marshall GM; Norris MD; Gudkov AV; Haber M, 2009, 'Small-Molecule Multidrug Resistance-Associated Protein 1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Models of Neuroblastoma', Cancer research, vol. 69, pp. 6573 - 6580, http://dx.doi.org/10.1158/0008-5472.CAN-09-1075

Raif A; Marshall GM; Bell J; Koach J; Tan O; D'andreti C; Thomas WD; Sekyere E; Norris MD; Haber M; Kavallaris M; Cheung BB, 2009, 'The estrogen-responsive B box protein (EBBP) restores retinoid sensitivity in retinoid-resistant cancer cells via effects on histone acetylation', Cancer Letters, vol. 277, pp. 82 - 90, http://dx.doi.org/10.1016/j.canlet.2008.11.030

Thomas WD; Chen J; Gao YR; Cheung BB; Koach J; Sekyere E; Norris MD; Haber M; Ellis T; Wainwright B; Marshall GM, 2009, 'Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression', Oncogene, vol. 28, pp. 1605 - 1615, http://dx.doi.org/10.1038/onc.2009.3

Bohlken A; Cheung B; Bell J; Koach J; Smith S; Sekyere E; Thomas WD; Norris MD; Haber M; Lovejoy DB; Richardson DR; Marshall GM, 2009, 'ATP7A is a novel target of retinoic acid receptor beta(2) in neuroblastoma cells', British Journal of Cancer, vol. 100, pp. 96 - 105, http://dx.doi.org/10.1038/sj.bjc.6604833

Ashton LJ; Gifford AJ; Kwan E; Lingwood A; Lau DTT; Marshall GM; Haber M; Norris MD, 2009, 'Reduced folate carrier and methylenetetrahydrofolate reductase gene polymorphisms: associations with clinical outcome in childhood acute lymphoblastic leukemia', Leukemia, vol. 23, pp. 1348 - 1351, http://dx.doi.org/10.1038/leu.2009.67

Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM; Haber M; Norris MD; Giles J, 2009, 'Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia', British Journal of Haematology, vol. 146, pp. 292 - 299, http://dx.doi.org/10.1111/j.1365-2141.2009.07744.x

Ambros PF; Ambros IM; Brodeur GM; Haber M; Khan J; Nakagawara A; Schleiermacher G; Speleman F; Spitz R; London WB; Cohn SL; Pearson ADJ; Maris JM, 2009, 'International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee', British Journal of Cancer, vol. 100, pp. 1471 - 1482, http://dx.doi.org/10.1038/sj.bjc.6605014

Ambros PF; Ambros IM; Brodeur GM; Haber M; Khan J; Nakagawara A; Schleiermacher G; Speleman F; Spitz R; London WB; Cohn SL; Pearson ADJ; Maris JM, 2009, 'International consensus for neuroblastoma molecular diagnostics: Report from the international neuroblastoma risk grouping (INRG) Biology committee', Klinische Pädiatrie, vol. 221, http://dx.doi.org/10.1055/s-0029-1222622

Henderson M; Choi S; Beesley A; Sutton R; Venn NC; Marshall GM; Kees UR; Haber M; Norris MD, 2008, 'Mechanism of relapse in pediatric acute lymphoblastic leukemia', Cell Cycle, vol. 7, pp. 1315 - 1320, http://dx.doi.org/10.4161/cc.7.10.5885

Hogarty MD; Norris MD; Davis K; Liu X; Evangeliou NF; Hayes CS; Pawel B; Guo R; Zhao H; Sekyere E; Keating J; Thomas WD; Cheng NC; Murray JE; Smith J; Sutton R; Venn NC; London WB; Buxton A; Gilmour SK; Marshall GM; Haber M, 2008, 'ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma', Cancer research, vol. 68, pp. 9735 - 9745, http://dx.doi.org/10.1158/0008-5472.CAN-07-6866

Sutton R; Lonergan MA; Tapp H; Venn NC; Haber M; O Brien T; Alvaro F; Revesz T; Norris MD, 2008, 'Two cases of hypereosinophilia and high-risk acute lymphoblastic leukemia', Leukemia, vol. 22, pp. 1463 - 1465, http://dx.doi.org/10.1038/sj.leu.2405096

Sutton R; Kwan EN; Giles JE; Venn NC; Tran S; Hackenberg N; Dalla Pozza L; Marshall GM; Haber M; van der Velden V; Norris MD; Bahar ; Giles J, 2008, 'Improving minimal residual disease detection in precursor B-ALL based on immunoglobulin-j and heavy-chain gene rearrangements', Leukemia, vol. 22, pp. 2265 - 2267, http://dx.doi.org/10.1038/leu.2008.121

Henderson M; Choi S; Beesley A; Baker DL; Wright DC; Papa R; Murch A; Campbell L; Lock RB; Norris MD; Haber M; Kees UR, 2008, 'A xenograft model of infant leukaemia reveals a complex MLL translocation', British Journal of Haematology, vol. 140, pp. 716 - 719, http://dx.doi.org/10.1111/j.1365-2141.2007.06966.x

Williams BB; Wall M; Miao RY; Williams B; Bertoncello I; Kershaw MH; Mantamadiotis T; Haber M; Norris MD; Gautam A; Darcy PK; Ramsay RG, 2008, 'Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer', Cancer Immunology and Immunotherapy, vol. 57, pp. 1635 - 1645, http://dx.doi.org/10.1007/s00262-008-0497-2

Smith DJ; Cossins LR; Hatzinisiriou I; Haber M; Nagley P, 2008, 'Lack of correlation between MYCN expression and the Warburg effect in neuroblastoma cell lines.', BMC Cancer, vol. 8, pp. 259, http://dx.doi.org/10.1186/1471-2407-8-251

Liu T; Tee AEL; Porro A; Smith SA; Dwarte T; Pei YL; Iraci N; Sekyere E; Haber M; Norris MD; Diolaiti D; Della Valle G; Perini G; Marshall GM, 2007, 'Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis (Proceedings of the National Academy of Science of the United States of America (November 20, 2007) 104; 47, (18682-18687) DOI: 10.1073/pnas.0705524104)', Proceedings of the National Academy of Sciences of the United States of America, vol. 104, pp. 21021, http://dx.doi.org/10.1073/pnas.0711060105

Liu T, 2007, 'Enhancing the anti-angiogenic action of histone deacetylase inhibitors', Molecular Cancer, vol. 6, pp. 68 - 79, http://dx.doi.org/10.1186/1476-4598-6-68

Liu T, 2007, 'Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis', Proceedings of the National Academy of Sciences of the United States of America, vol. 104, pp. 18682 - 18687, http://dx.doi.org/10.1073/pnas.0705524104

Xue C; Haber M; Flemming C; Marshall GM; Lock RB; Mackenzie K; Norris MD; Gurova K; Gudkov A, 2007, 'p53 determines multidrug sensitivity of childhood neuroblastoma.', Cancer research, vol. 67, pp. 10351 - 10360, http://dx.doi.org/10.1158/0008-5472.CAN-06-4345

Ashton LJ; Murray JE; Haber M; Marshall GM; Norris MD; Ashley DM, 2007, 'Polymorphisms in genes encoding drug metabolising enzymes and their influence on the outcome of children with neuroblastoma.', Pharmacogenetics and Genomics, vol. 17, pp. 709 - 717, http://dx.doi.org/10.1097/FPC.0b013e3280e1cc92

Choi S; Henderson M; Kwan EN; Sutton R; Giles J; Venn NC; Marshall GM; Haber M; Norris MD; Giles J, 2007, 'Relapse in children with acute lymphoblastic leukaemia involving selection of a pre-existing drug resistant subclone', Blood, vol. 110, pp. 632 - 639, http://dx.doi.org/10.1182/blood-2007-01-067785

Cheng AJ; Cheng NC; Smith J; Murray JE; Flemming C; Marshall GM; Norris MD; Haber M, 2007, 'Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma', European Journal of Cancer, vol. 43, pp. 1467 - 1475, http://dx.doi.org/10.1016/j.ejca.2007.03.008

Munoz MA; Henderson M; Haber M; Norris MD, 2007, 'Role of the MRP1/ABCC1 multidrug transporter protein in cancer', IUBMB Life, vol. 59, pp. 752 - 757, http://dx.doi.org/10.1080/15216540701736285

Ambros PF; Ambros IM; Brodeur GM; Haber M; Khan J; Nakagawara A; Schleiermacher G; Speleman F; Spitz R; Maris JM, 2007, '181 INVITED International consensus for neuroblastoma molecular diagnostics: report from the international neuroblastoma risk grouping (INRG) biology committee', European Journal of Cancer Supplements, vol. 5, pp. 48 - 48, http://dx.doi.org/10.1016/s1359-6349(07)70295-1

Cheung BB; Bell J; Raif A; Bohlken A; Yan J; Poljak A; Smith S; Lee M; Thomas WD; Kavallaris M; Norris MD; Haber M; Liu H; Zajchowski D; Marshall GM; bell , 2006, 'The estrogen-responsive B box protein is a novel regulator of the retinoid signal', The Journal of Biological Chemistry, vol. 281, pp. 18246 - 18256, http://dx.doi.org/10.1074/jbc.M600879200

Haber M; Smith J; Bordow SB; Flemming C; Cohn SL; London WB; Marshall GM; Norris MD, 2006, 'Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma', Journal of Clinical Oncology, vol. 24, pp. 1546 - 1553, http://dx.doi.org/10.1200/JCO.2005.01.6196

Norris MD; Smith J; Tanabe K; Tobin P; Flemming C; Scheffer G; Wielinga P; Cohn SL; London WB; Marshall GM; Allen JA; Haber M, 2005, 'Expression of multi-drug transport MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro', Molecular Cancer Therapeutics, vol. 4, pp. 547 - 553

Pajic M; Norris MD; Cohn RJ; Haber M, 2005, 'The role of the multidrug resistance-associated protein 1 gene in neuroblastoma biology and clinical outcome', Cancer Letters, vol. 228, pp. 241 - 246, http://dx.doi.org/10.1016/j.canlet.2005.01.060

Laughton SJ; Ashton LJ; Kwan EN; Norris MD; Haber M; Marshall GM, 2005, 'Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in childhood acute lymphoblastic leukaemia', Journal of Clinical Oncology, vol. 23, pp. 2264 - 2271, http://dx.doi.org/10.1200/JCO.2005.04.012

Liu T, 2005, 'The retinoid anticancer signal: mechanisms of target gene regulation', British Journal of Cancer, vol. 93, pp. 310 - 318, http://dx.doi.org/10.1038/sj.bjc.6602700

Norris MD; Smith J; Tanabe K; Tobin P; Flemming C; Scheffer G; Wielinga P; Cohn SL; London WB; Marshall GM; Allen JA; Haber M, 2005, 'Expression of multidrug ptransporter MRP4/ABCC4 is a marker of poor prognosis in nueroblastoma and confers resistance to irinotecan in vitro', Molecular Cancer Therapeutics, vol. 4, pp. 547 - 553, http://dx.doi.org/10.1158/1535-7163.MCT-04-0161

Liem N; Papa R; Milross CG; Schmid M; Tajbakhsh M; Choi S; Ramirez C; Rice AM; Haber M; Norris MD; Lock RB, 2004, 'Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies', Blood, vol. 103, pp. 3905 - 3914, http://dx.doi.org/10.1182/blood-2003-08-2911

Don S; Verrills NM; Liaw T; Haber M; Norris MD; Kavallaris M, 2004, 'Neuronal-associated microtubule proteins class III B-tubulin and MAP2c in neuroblastoma: Role in resistance to microtubule-targeted drugs.', Molecular Cancer Therapeutics, vol. 3, pp. 1137 - 1146

Hansford LM; Thomas WD; Keating JM; Burkhart C; Armati PJ; Weiss WA; Peaston AE; Norris MD; Haber M; Marshall GM, 2004, 'Mechanisms of embryonal tumor initination: Distinct roles for MycN expression and MYCN amlification.', Proceedings of the National Academy of Sciences of the United States of America, vol. 101, pp. 12664 - 12669, http://dx.doi.org/10.1073/pnas.0401083101

Manohar CF; Bray JA; Salwen H; Madafiglio J; Cheng AJ; Flemming C; Marshall GM; Norris MD; Haber M; Cohn SL, 2004, 'MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma', Oncogene, vol. 23, pp. 753 - 762, http://dx.doi.org/10.1038/sj.onc.1207151

Lastowska M; Chung Y; Ching Cheng C; Haber M; Norris MD; Kees UR; Pearson AA; Jackson M, 2004, 'Regions syntenic to human 17q are gained in mouse and rat neuroblastoma.', Genes Chromosomes and Cancer, vol. 40, pp. 158 - 163, http://dx.doi.org/10.1002/gcc.20031

Marshall G; Norris M; Haber M, 2003, 'Importance of minimal residual disease testing during the second year of disease: Still no answer? Reply', JOURNAL OF CLINICAL ONCOLOGY, vol. 21, pp. 4464 - 4465, http://dx.doi.org/10.1200/JCO.2003.99.188

Burkhart CA; Cheng AJ; Madafiglio J; Kavallaris M; Mili M; Marshall GM; Weiss WA; Khachigian LM; Norris MD; Haber M, 2003, 'Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma', Journal of National Cancer Institute, vol. 95, pp. 1394 - 1403, http://dx.doi.org/10.1093/jnci/djg045

Cheung BB; Yan JX; Smith SA; Nguyen TG; Lee M; Kavallaris M; Norris MD; Haber M; Marshall GM, 2003, 'Growth inhibitory retinoid effects after recruitment of retinoid X receptor B to the retinoic acid receptor B promoter', International Journal of Cancer, vol. 105, pp. 856 - 867, http://dx.doi.org/10.1002/ijc.11153

Verrills NM; Flemming C; Liu M; Ivery M; Cobon GS; Norris MD; Haber M; Kavallaris M, 2003, 'Microtubule alterations and mutations induced by desoxyepothilone B: Implications for drug-target', Chemistry and biology, vol. 10, pp. 597 - 607, http://dx.doi.org/10.1016/S1074-5521(03)00141-8

Hansford LM; Smith S; Haber M; Norris MD; Cheung BB; Marshall GM, 2003, 'Cloning and characterisation of the human neural cell adhesion molecule, (CNTN4) ( alias BIG-2)', Cytogenetic and Genome Research, vol. 101, pp. 1 - 17, http://dx.doi.org/10.1159/000073412

Nguyen TG; Hocker JE; Thomas WD; Smith SA; Norris MD; Haber M; Cheung BB; Marshall GM, 2003, 'Combined RAR and RXr-specific ligands overcome N-myc-associated retinoid resistance in neuroblastoma cells', Biochemical and Biophysical Research Communications, vol. 302, pp. 462 - 468, http://dx.doi.org/10.1016/S0006-291X(03)00177-3

Marshall GM; Haber M; Kwan EN; Zhu L; Ferrara D; Xue C; Brisco MJ; Sykes PJ; Morley A; Webster B; Dalla Pozza L; Waters K; Norris MD, 2003, 'Importance of minimal residual disease testing during teh second year of therapy for children with acute lymphoblastic leukemia', Journal of Clinical Oncology, vol. 21, pp. 704 - 709, http://dx.doi.org/10.1200/JCO.2003.10.080

Pearson AJ; Haber M; Norris MD; Xue C; Flemming C; Lunec J; Tweddle D, 2003, 'The p53 pathway and its inactivitation in neuroblastoma', Cancer Letters, vol. 197, pp. 93 - 98, http://dx.doi.org/10.1016/S0304-3835(03)00088-0

Houghton PJ; Adamson PC; Blaney S; Fine HA; Gorlick R; Haber M; Helman L; Hirschfeld S; Hollingshead MG; Israel MA; Lock RB; Maris JM; Merlino G; Patterson W; Reynolds CP; Shannon K; Yu A; Yu J; Smith MA, 2002, 'Testing of new agents in childhood cancer preclinical models(meeting summary)', Clinical Cancer Research, vol. 8, pp. 3646 - 3657

Lock RB; Liem N; Farnsworth ML; Milross CG; Xue C; Tajbakhsh M; Haber M; Norris MD; Marshall GM; Rice AM, 2002, 'The non-obese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of Childhood acute lymphblastic leukemia reveals intrinsic differences in biological characteristics at diagnosis and relapse', Blood, vol. 99, pp. 4100 - 4108, http://dx.doi.org/10.1182/blood.V99.11.4100

Gifford AJ; Haber M; Witt T; Whetstine JR; Taub JW; Matherly LH; Norris MD, 2002, 'Role of E45K reduced folate carrier gene mutation in methotrexate resistance in human leukaemia cells', Leukemia, vol. 16, pp. 2379 - 2387, http://dx.doi.org/10.1038/sj.leu.2402655

Burkhart CA; Norris MD; Haber M, 2002, 'A simple method for the isolation of genomic DNA from mouse tail free of real-time PCR inhibitors', Journal of Biochemical and Biophysical Methods, vol. 52, pp. 145 - 149, http://dx.doi.org/10.1016/S0165-022X(02)00052-0

Efferth T; Verdorfer I; Miyachi H; Sauerbrey A; Drexler H; Chitambar C; Haber M; Gebhart E, 2002, 'Genomic imbalances in drug-resistant T-cell acute lymphoblastic CEM leukemia cell lines', Blood Cells Molecules and Diseases, vol. 29, pp. 1 - 13, http://dx.doi.org/10.1006/bcmd.2002.0530

Norris MD; Madafiglio J; Gilbert J; Marshall GM; Haber M, 2001, 'Relationship between histopathological features, MYCN amplification, and prognosis: A UKCCSG study', Medical and Pediatric Oncology, vol. 36, pp. 169 - 176, http://dx.doi.org/10.1002/1096-911X(20010101)36:1<169::AID-MPO1041>3.0.CO;2-U

Norris MD; Gilbert J; Smith SA; Marshall GM; Salwen H; Cohn SL; Haber M, 2001, 'Genomic and allelic expression status of the p73 gene in human neuroblastoma', Medical and Pediatric Oncology, vol. 36, pp. 45 - 47, http://dx.doi.org/10.1002/1096-911X(20010101)36:1<45::AID-MPO1012>3.0.CO;2-E

Norris MD; Madafiglio J; Gilbert J; Marshall GM; Haber M, 2001, 'Reversal of multidrug resistance-associated protein-mediated drug resistance in cultured human neuroblastoma cells by the quinolone antibiotic difloxacin', MEDICAL AND PEDIATRIC ONCOLOGY, vol. 36, pp. 177 - 180, http://dx.doi.org/10.1002/1096-911X(20010101)36:1<177::AID-MPO1042>3.0.CO;2-Q

Norris MD; Gilbert J; Smith SA; Marshall GM; Salwen H; Cohn SL; Haber M, 2001, 'Expression of the putative tumour suppressor gene, p73, in neuroblastoma and other childhood tumours', Medical and Pediatric Oncology, vol. 36, pp. 48 - 51, http://dx.doi.org/10.1002/1096-911X(20010101)36:1<48::AID-MPO1013>3.0.CO;2-8

Norris MD; Marshall GM; Haber M; Gilbert J; Madafiglio J, 2001, 'Reversal of MRP-mediated drug resistance in cultured human neuroblastome cells by the quinlone antibiotic, difloxacin', Medical Pediatric Oncology, pp. 177 - 180

Catts VS; Haber M; Norris MD; Lutze-Mann L; Lock RB, 2001, 'High Level resistance to Glucocorticoids, assosiated with a dysfunctional glucocorticoid receptor, in childhood acute lymphoblastic leukemia cells selected for methotrexate resistance', Leukemia, vol. 15, pp. 929 - 935, http://dx.doi.org/10.1038/sj.leu.2402128

Kavallaris M; Tait AS; Norris MD; Haber M; Walsh B; He L; Horwitz SB, 2001, 'Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukemia cells', Cancer research, vol. 61, pp. 5803 - 5809

Marshall GM; Norris MD; Lock RB; Peaston AE; Gardaneh M; Franco VA; Hocker JE; Murphy K; Farnsworth ML; Catchpoole DR; Haber M, 2001, 'MRP1 gene expression level regulates the death and differentation response of neuroblastoma cells', British Journal of Cancer, vol. 85, pp. 1564 - 1571, http://dx.doi.org/10.1054/bjoc.2001.2144

Kwan E; Lal A; Haber M; Norris MD; Marshall GM, 2001, 'Detection of minimal residual disease in peripheral blood prior to clonical relapse of childhood acute lympohoblastic leukaemia using PCR', Molecular and Cellular Probes, vol. 15, pp. 99 - 103, http://dx.doi.org/10.1006/mcpr.2001.0348

Norris MD; Gilbert J; Smith A; Marshall GM; Salwen H; Cohn JN; Haber M, 2001, 'Expression of the Putative Tumour Suppressor Gene, p73, in Neuroblastome and Other Childhood Tumours', Medical Pediatric Oncology, vol. 36, pp. 48 - 51, http://dx.doi.org/10.1002/1096-911X(20010101)36:1<48::AID-MPO1013>3.0.CO;2-8

Ekert H; Vivekanandan S; Chow CW; Marshall GM; Haber M; Norris MD, 2001, 'Expression of GAGE genes in neuroblastoma by reverse transcription - polymerase chain reaction', Cancer Research Therapy and Control, vol. 11, pp. 197 - 203

Whetstine JR; Gifford AJ; Witt T; Liu X; Flatley RM; Norris MD; Haber M; Taub JW; Ravindranath Y; Matherly LH, 2001, 'Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G.A variant at position 80 and transport properties of the his27 And Arg27 carriers', Clinical Cancer Research, vol. 7, pp. 3416 - 3422, http://clincancerres.aacrjournals.org/content/7/11/3416.full-text.pdf

Cohn S; London WB; Huang K; Katzenstein HM; Salwen H; Reinhart T; Madafiglio J; Marshall GM; Norris MD; Haber M, 2000, 'MYCN expression is not prognostic of adverse outcomes in advanced-stage neuroblastoma with non-amplified MYCN', Journal of Clinical Oncology, vol. 18, pp. 3604 - 3613, http://dx.doi.org/10.1200/JCO.2000.18.21.3604

Norris MD; Burkhart CA; Marshall GM; Haber M, 2000, 'Expression of N-myc and MRP genes and their relationship to N-myc gene dosage and tumor formation in murine neuroblastoma model', Medical and Pediatric Oncology, vol. 35, pp. 585 - 589, http://dx.doi.org/10.1002/1096-911X(20001201)35:6<585::AID-MPO20>3.0.CO;2-P

Kwan EN; Norris MD; Zhu L; Ferrara D; Marshall GM; Haber M, 2000, 'Simultaneous detection and quantification of minimal residual disease in childhood acute lymphoblastic leukaemia using real-time polymerase chain reaction', British Journal of Haematology, vol. 109, pp. 430 - 434, http://dx.doi.org/10.1046/j.1365-2141.2000.02029.x

Gardaneh M; Gilbert J; Haber M; Norris MD; Marshall GM, 2000, 'Synergy between 5` and 3` flanking regions of the human tyrosine hydroxylase gene ensures specific, high-level expression in neuroblastoma cells', Neuroscience Letters, vol. 292, pp. 147 - 150, http://dx.doi.org/10.1016/S0304-3940(00)01474-9

Marshall GM; Haber M; Kwan E; Zhou L; Ferrara D; Williams S; Brisco MJ; Morley A; Webster B; Dalla Pozza L; Tucker D; Waters K; Norris MD, 1999, 'The effect of late intensification of therapy in children with acute lymphoblastic leukaemia and minimal residual disease.', BLOOD, vol. 94, pp. 658A - 658A, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000083790302970&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Haber M; Bordow SB; Gilbert J; Madafiglio J; Kavallaris M; Marshall GM; Mechetner EB; Fruehauf JP; Tee L; Cohn S; Salwen H; Schmidt ML; Norris MD; Gilbert J, 1999, 'Altered expression of the MYCN Oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells', Oncogene, vol. 18, pp. 2777 - 2782, http://dx.doi.org/10.1038/sj.onc.1202859

Gilbert J; Haber M; Bordow SB; Marshall GM; Norris MD, 1999, 'Use of tumor-specific gene expression for the differential diagnosis of neuroblastoma from other pediatric small-round-cell malignancies', American Journal of Pathology, vol. 155, pp. 17 - 21, http://dx.doi.org/10.1016/S0002-9440(10)65093-6

Gifford AJ; Kavallaris M; Madafiglio J; Matherly LH; Stewart BW; Haber M; Norris MD, 1998, 'P-glycoprotein-mediated methotrexate resistance in CCRF-CEM sublines deficient in Methotrexate accumulation due to a point mutation in the reduced folate carrier gene', International Journal of Cancer, vol. 78, pp. 176 - 181, http://dx.doi.org/10.1002/(SICI)1097-0215(19981005)78:2<176::AID-IJC10>3.0.CO;2-9

Kavallaris M; Gardaneh M; Cheung BB; Camacho M; Hocker JE; Norris MD; Haber M; Marshall GM, 1998, 'In Vitro effects of MYCN sense and antisense expression in MYCN-amplified human neuroblastoma cells', Anticancer Research, vol. 18, pp. 1793 - 1798

Lal A; Kwan EN; Al Mahr M; Zhou L; Ferrara D; Tobias VH; O Gorman-Hughes DW; Haber M; Norris MD; Marshall GM, 1998, 'Molecular detection of acute Lymphoblastic Leukaemia in boys with testicular relapse', Molecular Pathology, vol. 51, pp. 277 - 281, http://dx.doi.org/10.1136/mp.51.5.277

Bardow SB; Norris MD; Haber PS; Marshall GM; Haber M, 1998, 'Prognostic significance of MYCN oncgene expression in childhood neuroblastoma', Journal of Clinical Oncology, vol. 16, pp. 3286 - 3294, http://dx.doi.org/10.1200/JCO.1998.16.10.3286

Cheung BB; Hocker JE; Smith S; Norris MD; Haber M; Marshall GM, 1998, 'Favorable prognostic signifiance of high-level retinoic acid receptor B expression in neuroblastoma mediated by effects on cell cycle regulation', Oncogene, vol. 17, pp. 751 - 759, http://dx.doi.org/10.1038/sj.onc.1201982

Preston AE; Camacho M; Norris MD; Haber M; Marsh DJ; Robinson BG; Hyland V; Marshall GM, 1998, 'Absence of MEN2A- or 2B- type RET mutations in primary neuroblastoma tumour tissue', Molecular and Cellular Probes, vol. 12, pp. 239 - 242, http://dx.doi.org/10.1006/mcpr.1998.0181

Gilbert J; Norris MD; Marshall GM; Haber M, 1997, 'Low specificity of PGP9.5 expression for detection of micrometastatic neuroblastoma', British Journal of Cancer, vol. 75, pp. 1779 - 1781, http://dx.doi.org/10.1038/bjc.1997.303

Haber M; Bordow SB; Haber PS; Marshall GM; Stewart BW; Norris MD, 1997, 'THE PROGNOSTIC VALUE OF MDR1 GENE EXPRESSION IN PRIMARY UNTREATED NEUROBLASTOMA', EUR Journal CANCER, vol. 33, pp. 2031 - 2036, http://dx.doi.org/10.1016/S0959-8049(97)00229-3

Norris MD; Bordow SB; Haber PS; Marshall GM; Kavallaris M; Madafiglio J; Cohn S; Schmidt ML; Hipfner DR; Deeley RG; Cole SP; Haber M; Salwen H, 1997, 'EVIDENCE THAT THE N-MYC ONCOGENE REGULATES MRP GENE EXPRESSION IN NEUROBLASTOMA', European Journal of Cancer, vol. 33, pp. 1911 - 1916, http://dx.doi.org/10.1016/S0959-8049(97)00284-0

Kavallaris M; Kuo DY; Burkhart CA; Regl DL; Norris MD; Haber M; Horwitz SB, 1997, 'TAXOL-RESISTANT EPITHELIAL OVARIAN TUMORS ARE ASSOCIATED WITH ALTERED EXPRESSION OF SPECIFIC {BETA}-TUBLIN ISOTYPES', Journal of Clinical Investigation, vol. 100, pp. 1282 - 1293, http://dx.doi.org/10.1172/JCI119642

Marshall GM; Peaston AE; Hocker JE; Smith AJ; Hansford LM; Tobias VH; Norris MD; Haber M; Smith DD; Lorenzo MJ; Ponder BJ; Hancock JF, 1997, 'Expression of multiple endocrine neoplasia 2B ret in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behaviour in vivo, and activates jun kinase 1', Cancer research, vol. 57, pp. 5399 - 5405

Haber M; Kwan EN; Zhu L; Marshall GM; Norris MD, 1997, 'SENSITIVE NON- RADIOACTIVE PCR DETECTION OF CLONAL T-CELL RECEPTOR GAMMA GENE REARRANGEMENTS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA', British Journal of Haematology, vol. 98, pp. 995 - 998, http://dx.doi.org/10.1046/j.1365-2141.1997.3243143.x

Norris MD; Kwan EN; Zhu L; Ferrara D; Marshall GM; Haber M, 1997, 'IMPROVED PCR ASSAY FOR THE DETECTION OF ANTIGEN RECEPTOR GENE REARRANGEMENTS', Journal of Biochemical and Biophysical Methods, vol. 36, pp. 3 - 10, http://dx.doi.org/10.1016/S0165-022X(97)00043-2

Castleberry RP; Pritchard JE; Ambros P; Berthold F; Brodeur GM; Castel V; Cohn S; Debernardi B; Dicksmireaux C; Frappaz D; Haase GM; Haber M, 1997, 'THE INTERNATIONAL NEUROBLASTOMA RISK GROUPS (INRG) - A PRELIMINARY REPORT', EUR Journal CANCER, vol. 33, pp. 2113 - 2116, http://dx.doi.org/10.1016/S0959-8049(97)00202-5

Norris MD; Kwan E; Zhu L; Marshall GM; Haber M, 1996, 'Sensitive non radioactive PCR detection of minimal residual leukaemia using TCR(gamma) gene rearrangements', BRITISH JOURNAL OF HAEMATOLOGY, vol. 93, pp. 225 - 225, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1996UP11400225&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Norris MD; Bordow SB; Marshall GM; Heber PS; Cohn S; Haber M, 1996, 'Association between high levels of expression of the multidrug resistance-associated protein (MRP) gene and poor outcome in primary human neuroblastoma', New England Journal of Medicine, pp. 231 - 238

Norris MD; Bordow SB; Marshall GM; Haber PS; Cohn S; Haber M, 1996, 'Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma', New England Journal of Medicine, vol. 334, pp. 231 - 238, http://dx.doi.org/10.1056/NEJM199601253340405

Norris MD; De Graaf D; Haber M; Kavallaris M; Madafiglio J; Gilbert J; Kwan E; Stewart BW; Mechetner EB; Gudkov AV; Roninson IB, 1996, 'Involvement of MDR1 P-Glycoprotein in multifactorial resistance to methotrexate', International Journal of Cancer, vol. 65, pp. 613 - 619, http://dx.doi.org/10.1002/(SICI)1097-0215(19960301)65:5<613::AID-IJC10>3.0.CO;2-8

Cheung BB; Hocker JE; Smith SA; Reichert U; Norris MD; Haber M; Stewart BW; Marshall GM, 1996, 'Retinoic acid receptors B and g distinguish retinoid signals for growth inhibition and neuritogenesis in human neuroblastoma cells', Biochemical and Biophysical Research Communications, vol. 229, pp. 349 - 354, http://dx.doi.org/10.1006/bbrc.1996.1804

Haber M; Burkhart CA; Regl DL; Madafiglio J; Norris MD; Horwitz SB, 1995, 'Altered expression of Mβ2, the class II β-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance', Journal of Biological Chemistry, vol. 270, pp. 31269 - 31275, http://dx.doi.org/10.1074/jbc.270.52.31269

Norris MD; Gilbert J; Madafiglio J; Haber M, 1995, 'Analysis of a novel cDNA encoding a C219-reactive peptide isolated from methotrexate-selected multidrug-resistant human leukemic cells', Gene, vol. 156, pp. 313 - 314, http://dx.doi.org/10.1016/0378-1119(94)00541-Y

Haber M; Norris MD; Kavallaris M; Camacho M; Madafiglio J; Baker C; White L; Stewart BW, 1995, 'An assay for the determination of reduced methotrexate accumulation in cells displaying limited viability in vitro', Cancer Letters, vol. 97, pp. 49 - 55, http://dx.doi.org/10.1016/0304-3835(95)03950-2

Norris MD; Kwan EN; Haber M; Marshall GM, 1995, 'Detection of evolving immunoglobin heavy chain gene rearrangements in acute lymphoblastic leukemia: a PCR-based assay employing overlapping DHh primers', Leukemia, vol. 9, pp. 1779 - 1782

Marshall GM; Cheung BB; Stacey KP; Camacho M; Simpson AM; Kwan EN; Smith S; Haber M; Norris MD, 1995, 'Increased retinoic acid receptor gamma expression suppresses the malignant phenotype and alters the differentiation potential of human neuroblastoma cells', Oncogene, vol. 11, pp. 485 - 491

Marshall GM; Kwan EN; Haber M; Brisco MJ; Sykes PJ; Morley A; Toogood I; Waters K; Tauro G; Ekert H; Norris MD, 1995, 'Characterisation of clonal immunoglobulin heavy chain and T-cell receptor y gene rearrangements during progression of childhood acute lymphoblastic leukemia', Leukemia, vol. 9, pp. 1847 - 1850

Bordow SB; Haber M; Madaflglio J; Cheung B; Marshall GM; Norris MD, 1994, 'Expression of the Multidrug Resistance-associated Protein (MRP) Gene Correlates with Amplification and Overexpression of the N-myc Oncogene in Childhood Neuroblastoma', Cancer Research, vol. 54, pp. 5036 - 5040

MARSHALL GM; CHEUNG B; STACEY KP; NORRIS MD; HABER M, 1994, 'REGULATION OF RETINOIC ACID RECEPTOR-ALPHA EXPRESSION IN HUMAN NEUROBLASTOMA CELL-LINES AND TUMOR-TISSUE', ANTICANCER RESEARCH, vol. 14, pp. 437 - 441, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1994NR46300017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Norris MD; Haber M; Gilbert J; Kavallaris M; Marshall GM; Stewart BW, 1994, 'N-myc gene amplification in neuroblastoma determined by the polymerase chain reaction.', Progress in clinical and biological research, vol. 385, pp. 27 - 33

Haber M; Madafiglio J; Bordow SB; Gilbert J; Cheung B; Marshall GM; Norris MD, 1994, 'Expression of retinoic acid-responsive genes in primary neuroblastomas.', Progress in clinical and biological research, vol. 385, pp. 245 - 251

Marshall GM; Cheung B; Stacey KP; Norris MD; Haber M, 1994, 'Regulation of retinoic acid receptor alpha expression in human neuroblastoma cell lines and tumor tissue', Anticancer Research, vol. 14, pp. 437 - 441

Haber M; Madafiglio J; Norris MD, 1993, 'Methotrexate cytotoxicity determination using the MTT assay following enzymatic depletion of thymidine and hypoxanthine', Journal of Cancer Research and Clinical Oncology, vol. 119, pp. 315 - 317, http://dx.doi.org/10.1007/BF01208836

Kavallaris M; Madafiglio J; Norris MD; Haber M, 1993, 'Resistance to Tetracycline, a Hydrophilic Antibiotic, Is Mediated by P-Glycoprotein in Human Multidrug-Resistant Cells', Biochemical and Biophysical Research Communications, vol. 190, pp. 79 - 85, http://dx.doi.org/10.1006/bbrc.1993.1013

Gilbert J; Norris MD; Haber M; Kavallaris M; Marshall GM; Stewart BW, 1993, 'Determination of n-myc gene amplification in neuroblastoma by differential polymerase chain reaction', Molecular and Cellular Probes, vol. 7, pp. 227 - 234, http://dx.doi.org/10.1006/mcpr.1993.1033

Selig RA; Madafiglio J; Haber M; Norris MD; White L; Stewart BW, 1993, 'Ferritin production and desferrioxamine cytotoxicity in human neuroblastoma cell lines', Anticancer Research, vol. 13, pp. 721 - 725

Norris MD; Haber M; Kavallaris M; Brian MJ; Lutze LH; White L; Stewart BW, 1991, 'Reduced drug accumulation as the mechanism of extreme clinical resistance to methotrexate in the human T‐cell leukemia xenograft, LALW‐2', Cancer, vol. 68, pp. 981 - 987, http://dx.doi.org/10.1002/1097-0142(19910901)68:5<981::AID-CNCR2820680512>3.0.CO;2-W

Kavallaris M; Haber M; Norris MD; Matherly LH; Stewart BW, 1991, 'Characterization of Mechanisms Mediating Drug Resistance in Human Leukemic Cells Selected with High Concentration Methotrexate', Pteridines, vol. 3, pp. 119 - 121, http://dx.doi.org/10.1515/pteridines.1991.3.12.119

Kavallaris M; Haber M; Norris MD; Pittman SM; Reed C; Stewart BW, 1990, 'Phenotypic and cytogenetic analysis of atypical multidrug resistance in human leukaemic cells selected with methotrexate at high concentration', Cancer Letters, vol. 51, pp. 193 - 201, http://dx.doi.org/10.1016/0304-3835(90)90102-4

Norris MD; Haber M; King M; Davey RA, 1989, 'Atypical multidrug resistance in CCRF-CEM cells selected for high level methotrexate resistance: Reactivity to monoclonal antibody C219 in the absence of P-glycoprotein expression', Biochemical and Biophysical Research Communications, vol. 165, pp. 1435 - 1441, http://dx.doi.org/10.1016/0006-291X(89)92764-2

Haber M; Norris MD; Kavallaris M; White L; Stewart BW; Bell DR; Davey RA, 1989, 'Atypical Multidrug Resistance in a Therapy-induced Drug-resistant Human Leukemia Cell Line (LALW-2): Resistance to Vinca Alkaloids Independent of P-Glycoprotein', Cancer Research, vol. 49, pp. 5281 - 5287

Haber M; Reed C; Kavallaris M; Norris MD; Stewart BW, 1989, 'Resistance to drugs associated with the multidrug resistance phenotype following selection with high-concentration methotrexate', Journal of the National Cancer Institute, vol. 81, pp. 1250 - 1254, http://dx.doi.org/10.1093/jnci/81.16.1250

White L; Haber M; Brian MJ; Norris MD; Trickett A; Sosula L; Tiley C; Stewart BW, 1989, 'Therapy‐induced drug resistance in a human leukemia line (LALW‐2)', Cancer, vol. 63, pp. 2103 - 2110, http://dx.doi.org/10.1002/1097-0142(19890601)63:11<2103::AID-CNCR2820631106>3.0.CO;2-N

Stewart BW; Haber M; Ward EJ, 1986, 'Digestion of repair sites in rat liver DNA by endogenous nucleases.', Biochemistry International, vol. 13, pp. 903 - 913

HABER M; KAVALLARIS M; STEWART BW, 1986, '2-STAGE INCORPORATION OF THYMIDINE TRIPHOSPHATE INTO MAMMALIAN DNA AS INDICATED BY CHROMATOGRAPHY ON BENZOYLATED DEAE-CELLULOSE', JOURNAL OF CHROMATOGRAPHY, vol. 382, pp. 127 - 134, http://dx.doi.org/10.1016/S0378-4347(00)83511-2

Haber M; Kavallaris M; Stewart BW, 1986, 'Two-stage incorporation of thymidine triphosphate into mammalian DNA as indicated by chromatography on benzoylated DEAE-cellulose', Journal of Chromatography B: Biomedical Sciences and Applications, vol. 382, pp. 135 - 145, http://dx.doi.org/10.1016/S0378-4347(00)83512-4

Haber M; Kavallaris M; Stewart BW, 1986, 'Two-stage incorporation of thymidine triphosphate into mammalian DNA as indicated by chromatography on benzoylated DEAE-cellulose', Journal of Chromatography - Biomedical Applications, vol. Vol. 382, pp. 127 - 134

Ward EJ; Haber M; Norris MD; Stewart BW, 1985, 'Single-Strand-Specific Degradation of DNA during Isolation of Rat Liver Nuclei†', Biochemistry, vol. 24, pp. 5803 - 5809, http://dx.doi.org/10.1021/bi00342a018

STEWART BW; HRISTOFORDIS C; HABER M; WARD EJ, 1985, 'ENHANCEMENT OF NITROSAMINE-INDUCED STRUCTURAL DAMAGE IN RAT-LIVER DNA BY CELL-DIVISION', PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 26, pp. 97 - 97, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1985AGD9400383&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Haber M; Stewart BW, 1985, 'Patterns of structural change in DNA during tissue necrosis indicated by benzoylated DEAE-cellulose chromatography', Chemico-Biological Interactions, vol. 53, pp. 247 - 255, http://dx.doi.org/10.1016/S0009-2797(85)80102-2

Stewart BW; Hristoforidis C; Haber M, 1985, 'Dose-dependent persistence of alkylation-induced single stranded regions in rat liver DNA in vivo', Cancer Letters, vol. 28, pp. 27 - 33, http://dx.doi.org/10.1016/0304-3835(85)90088-6

Stewart BW; Hristofordis C; Haber M; Ward EJ, 1985, 'Enhancement of nitrosamine-induced structural damage in rat liver DNA by cell division', Proceedings of the American Association for Cancer Research, vol. VOL. 26

Haber M; Stewart BW, 1985, 'Oncogenes. A possible role for cancer genes in human malignant disease', Medical Journal of Australia, vol. 142, pp. 402 - 409, http://dx.doi.org/10.5694/j.1326-5377.1985.tb133155.x

Haber M; Huang PHT; Stewart BW, 1984, 'Limitations on the stability of benzoylated DEAE-cellulose', Analytical Biochemistry, vol. 139, pp. 363 - 366, http://dx.doi.org/10.1016/0003-2697(84)90018-6

WARD EJ; HABER M; STEWART BW, 1984, 'DIFFERENTIAL REPAIR OF ALKYLATION DAMAGE IN RAT-LIVER CHROMATIN', MEDICAL AND PEDIATRIC ONCOLOGY, vol. 12, pp. 278 - 279, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1984TC60000027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

STEWART BW; HABER M; HRISTOFORIDIS C, 1984, 'FACTORS AFFECTING THE PERSISTENCE OF ALKYLATION-INDUCED STRUCTURAL DAMAGE IN DNA INVIVO', PROCEEDINGS OF THE AUSTRALIAN BIOCHEMICAL SOCIETY, vol. 16, pp. S18 - S18, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1984ANC4600033&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

HABER M; STEWART BW, 1983, 'STRUCTURAL INTERMEDIATES GENERATED DURING REPLICATION OF MAMMALIAN DNA', MEDICAL AND PEDIATRIC ONCOLOGY, vol. 11, pp. 198 - 199, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1983QX04200045&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

HABER M; STEWART BW, 1983, 'REPLICATIVE INTERMEDIATES IN MAMMALIAN DNA', PROCEEDINGS OF THE AUSTRALIAN BIOCHEMICAL SOCIETY, vol. 15, pp. 69 - 69, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1983RC51300166&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Haber M; Stewart BW, 1981, 'Sizing of DNA fragments by preparative, benzoylated DEAE-cellulose chromatography', FEBS Letters, vol. 133, pp. 72 - 74, http://dx.doi.org/10.1016/0014-5793(81)80473-5

HABER M; STEWART BW, 1981, 'ANALYSIS OF CHEMICALLY-INDUCED STRUCTURAL-CHANGE IN DNA BY BENZOYLATED-DEAE-CELLULOSE CHROMATOGRAPHY', PROCEEDINGS OF THE AUSTRALIAN BIOCHEMICAL SOCIETY, vol. 14, pp. 90 - 90, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1981LR25400218&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers

Nagy Z; Kanikevich M; Koach J; Mayoh C; Carter D; Liu T; Du Y; Jiang C; Haber M; Norris M; Cheung B; Marshall G, 2019, 'Abstract 3659: Alyref is a novel binding partner and co-factor for MYCN-driven oncogenesis in neuroblastoma', in Tumor Biology, American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.sabcs18-3659

Valli E; Xue C; Cheung L; Gamble L; Pandher R; Giacomo SD; Burkhart C; Fedtsova N; Ferrucci F; Makarov S; Telfer T; Codd R; Scott D; Perini G; Osterman A; Gudkov A; Norris M; Haber M, 2019, 'Abstract 2616: A novel iron-chelating agent reduces MYC transcription via E2F gene family regulation', in Molecular and Cellular Biology / Genetics, American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.sabcs18-2616

Valli E; Xue C; Cheung L; Gamble L; Pandher R; Di Giacomo S; Burkhart C; Fedtsova N; Ferrucci F; Makarov S; Telfer T; Codd R; Scott D; Perini G; Osterman A; Gudkov A; Norris M; Haber M, 2019, 'A novel iron-chelating agent reduces MYC transcription via E2F gene family regulation', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Atlanta, GA, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Atlanta, GA, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-2616

Tee AE; Liu PY; Milazzo G; Hannan KM; Maag J; Bartonicek N; Song R; Jiang CC; Zhang XD; Norris MD; Haber M; Marshall GM; Li J; Vandesompele J; Mattick JS; Mestdagh P; Perini G; Hannan RD; Dinger ME; Liu T, 2018, 'Eradication of neuroblastoma by suppressing the expression of a single noncoding RNA', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Chicago, IL, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Chicago, IL, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-2453

Gao J; Somers K; Hannan KM; Fletcher JI; Liu B; Hannan RD; Pearson RB; Haber M; Norris MD; Henderson MJ, 2017, 'Abstract 1956: ABCE1 regulates the translational profile of neuroblastoma to drive tumor progression', in Tumor Biology, American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC, http://dx.doi.org/10.1158/1538-7445.am2017-1956

Flynn AT; Vu A; Liu K; Scadden E; Attiyeh E; Norris M; Haber M; Hogarty M, 2017, 'Abstract 4883: Targeting tumor-amplifiedODC1with difluoromethylornithine (DFMO) inhibits global protein translation and has antitumor activity in neuroblastoma', in Tumor Biology, American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC, http://dx.doi.org/10.1158/1538-7445.am2017-4883

Somers K; Middlemiss S; Biktasova A; Karsa M; Cheung L; Kosciolek A; Evans K; Mayoh C; Kees UR; Korotchkina L; Chernova OB; Lock RB; Gudkov AV; Haber M; Norris MD; Henderson MJ, 2017, 'Inhibition of NAMPT as a novel therapeutic strategy for infant leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Washington, DC, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC, 01 April 2017 - 05 April 2017, http://dx.doi.org/10.1158/1538-7445.AM2017-1175

Gana CC; Hanssen K; Yu DM; Flemming C; Norris M; Haber M; Fletcher J, 2017, 'A modulator of multidrug resistance protein 1 selectively depletes glutathione and synergizes with L-buthionine sulfoximine to sensitize MRP1-expressing cancer cells to chemotherapy', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Washington, DC, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC, 01 April 2017 - 05 April 2017, http://dx.doi.org/10.1158/1538-7445.AM2017-4056

Burns MR; Fosnaugh K; Palfreyman MG; Gamble L; Murray J; Allan S; Eden G; Sarraf S; Norris M; Ziegler D; Haber M, 2017, 'AMX-513 polyamine depletion therapy inhibits tumor growth and reverses immunosuppression in cancers including MYC-driven neuroblastoma and pancreatic cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Washington, DC, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC, 01 April 2017 - 05 April 2017, http://dx.doi.org/10.1158/1538-7445.AM2017-2006

Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Russell A; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD, 2016, 'Abstract 2450: MYCN and TFAP4 promote neuroblastoma malignancy by cooperating in the regulation a subset of target genes involved in cancer cell growth and metastasis', in Tumor Biology, American Association for Cancer Research, presented at Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA, http://dx.doi.org/10.1158/1538-7445.am2016-2450

Koach J; Murray JE; McCarroll J; Milazzo G; Perini G; Haber M; Norris MD; Fletcher JI; Cheung BB; Marshall GM, 2016, 'Targeting PA2G4, a novel MYCN co-factor, for the treatment of neuroblastoma', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, pp. S7 - S7, http://dx.doi.org/10.1016/S0959-8049(16)61016-X

Vittorio O; Brandl M; Cirillo G; Kimpton K; Hinde E; Duong HTT; Boyer C; Flemming C; Yee EMH; Kumar N; Parmar A; Pascali G; Charil A; Haber M; Norris M; Kavallaris M, 2016, 'Dextran-Catechin conjugate: An anticancer nano-modified natural compound targeting copper metabolism in neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, New Orleans, LA, presented at 107th Annual Meeting of the American-Association-of-Cancer-Research (AACR), New Orleans, LA, 16 April 2016 - 20 April 2016, http://dx.doi.org/10.1158/1538-7445.AM2016-1340

Wadham C; Saletta F; Byrne JA; Trahair T; Ziegler DS; McCowage G; Marshall G; Haber M; Norris M, 2015, 'Molecular profiling of relapsed childhood cancer', in CLINICAL CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Salt Lake, UT, presented at Meeting of the American-Association-for-Cancer-Research (AACR) Precision Medicine Series - Integrating Clinical Genomics and Cancer Therapy, Salt Lake, UT, 13 June 2015 - 16 June 2015, http://dx.doi.org/10.1158/1557-3265.PMSCLINGEN15-51

Koach J; Liu B; Bell JL; Huettelmaier S; Liu T; Carter DR; Haber M; Norris MD; Fletcher J; Cheung BB; Marshall GM, 2015, 'PA2G4 predicts poor prognosis in neuroblastoma patients and promotes neuroblastoma progression by enhancing MYCN protein stability', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Philadelphia, PA, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Philadelphia, PA, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-962

O'Brien R; Maritz MF; Kong CF; Purgato S; Liu B; Yang C; Russell A; Murray J; Flemming C; Haber M; Perini G; Norris MD; Fletcher JI; Mackenzie KL, 2015, 'High DKC1 expression supports neuroblastoma tumor cell proliferation and is strongly associated with poor patient outcomes', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Philadelphia, PA, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Philadelphia, PA, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-488

Williams R; Russell A; Bongers A; Sagnella S; Fife C; Jessup W; DeFazio A; Chenevix-Trench G; Haber M; Norris M; Henderson M, 2015, 'Examining the role of ABCA1 cholesterol transporter in ovarian cancer spheroids', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Philadelphia, PA, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Philadelphia, PA, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-313

Carter DR; Murray J; Cheung BB; Kalla H; Gamble L; Tsang J; Sutton S; Koach J; Syed S; Gifford A; Issaeva N; Biktasova A; Atmadibrata B; Sun Y; Sokolowski N; Ling D; Kim PY; Webber H; Clark A; Ruhle M; Liu B; Oberthuer A; Fischer M; Byrne J; Saletta F; Purmal A; Ziegler D; Liu T; Gurova KV; Gudkov AV; Norris MD; Haber M; Marshall GM, 2015, 'MYCN and is a therapeutic target in neuroblastoma', in MOLECULAR CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, La Jolla, CA, presented at AACR Special Conference on Myc - From Biology to Therapy, La Jolla, CA, 07 January 2015 - 10 January 2015, http://dx.doi.org/10.1158/1557-3125,MYC15-PRO9

Haber M; Murray J; Gamble L; Carnegie-Clark A; Webber H; Ruhle M; Carter D; Oberthur A; Fischer M; Ziegler D; Marshall GM; Gurova K; Burkhart C; Purmal A; Gudkov AV; Norris MD, 2014, 'CBL0137, a novel NFkB suppressor and p53 activator, is highly effective in pre-clinical models of neuroblastoma', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, European Org Res & Treatment Canc, Barcelona, SPAIN, pp. 135 - 135, presented at 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, European Org Res & Treatment Canc, Barcelona, SPAIN, 18 November 2014 - 21 November 2014, http://dx.doi.org/10.1016/S0959-8049(14)70548-9

Tsoli M; Vanniasinghe A; Luk P; Dilda P; Haber M; Hogg P; Ziegler D, 2014, 'TARGETING MITOCHONDRIA AND CELL METABOLISM AS A NOVEL THERAPEUTIC APPROACH IN THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Singapore, SINGAPORE, pp. 47 - 47, presented at 16th International Symposium on Pediatric Neuro-Oncology (ISPNO), Singapore, SINGAPORE, 28 June 2014 - 02 July 2014, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000337924200179&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Tsoli M; Luk P; Dilda P; Hogg P; Haber M; Ziegler D, 2013, 'TARGETING MITOCHONDRIA AND METABOLISM AS A NOVEL THERAPEUTIC APPROACH IN THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Fort Lauderdale, FL, pp. 21 - 21, presented at 2nd Annual Pediatric Neuro-Oncology Basic and Translational Research Conference, Fort Lauderdale, FL, 16 May 2013 - 17 May 2013, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318570500078&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Carter DR; Cheung BB; Liu T; Liu C; Norris MD; Haber M; Murray J; Gurova KV; Gudkov AV; Marshall GM, 2013, 'The facilitates chromatin transcription (FACT) protein complex promotes neuroblastoma tumor initiation.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Washington, DC, presented at 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC, 06 April 2013 - 10 April 2013, http://dx.doi.org/10.1158/1538-7445.AM2013-5043

Norris MD; Gamble LD; Murray J; Purqato S; Miiazzo G; Ashton LJ; Oberthuer A; London WB; Hogarty MD; Fischer M; Ziegler D; Marshall GM; Perini G; Haber M, 2013, 'MYCN coordinately regulates the entire polyamine gene pathway to drive polyamine biosynthesis in neuroblastoma, with expression of every synthetic and catabolic polyamine pathway gene being highly prognostic of clinical outcome', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Washington, DC, presented at 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC, 06 April 2013 - 10 April 2013, http://dx.doi.org/10.1158/1538-7445.AM2013-3808

Haber M; Murray J; Carnegie-Clark A; Webber H; Marshall GM; Gurova KV; Burkhart CA; Purmai A; Gudkov AV; Norris MD, 2013, 'Anticancer compound curaxin CBL0137, that simultaneously suppresses NF-kappa B and activates p53, is highly effective in two independent mouse models of neuroblastoma.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Washington, DC, presented at 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC, 06 April 2013 - 10 April 2013, http://dx.doi.org/10.1158/1538-7445.AM2013-2759

Norris MD; Fletcher JI; Gherardi S; Murray J; Burkhart C; Russell A; Valli E; Oberthuer A; Ashton LJ; London WB; Marshall GM; Perini G; Haber M, 2012, 'GSTP1 expression is regulated by MycN and is a marker of poor outcome in childhood neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1538-7445.AM2012-789

Huynh T; Tivnan A; Munoz M; Cheung L; Vishvanath A; Flemming C; Watt F; Burkhart C; Gudkov A; Fletcher J; Henderson M; Norris M; Haber M, 2012, 'Targeting ABC transporters in cancer through small molecule inhibitors', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, presented at Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL, http://dx.doi.org/10.1158/1538-7445.AM2012-1834

Lau DT; Norris MD; Marshall GM; Haber M; Ashton LJ, 2011, 'New evidence supports the potential use of methotrexate in children with MYCN-amplified neuroblastoma.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1538-7445.AM2011-LB-367

Norris MD; Henderson MJ; Porro A; Munoz M; Iraci N; Xue C; Murray J; Flemming C; Fletcher J; Gherardi S; Kwek A; Russell A; London WB; Buxton AB; Ashton L; Sartorelli AC; Cohn SL; Schwab M; Marshall GM; Perini G; Haber M, 2011, 'ABCC/MRP multidrug transporters contribute to neuroblastoma biology, pathogenesis and clinical outcome, independently of any role in cytotoxic drug efflux', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1538-7445.AM2011-954

Henderson MJ; Hedditch EL; Russell AJ; deFazio A; Emmanuel C; George J; Chenevix-Trench G; Bowtell D; Norris MD; Haber M, 2011, 'Cholesterol efflux transporter gene expression predicts clinical outcome in serous ovarian cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, presented at Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL, http://dx.doi.org/10.1158/1538-7445.AM2011-1660

Xue C; Cheung L; Norris MD; Haber M; Burkhart C; Fedtsova N; Gudkov A; Makarov SS, 2011, 'Abstract 617: Small molecule that simultaneously inhibits Myc oncoprotein and activates HIF1A', in Experimental and Molecular Therapeutics, American Association for Cancer Research, presented at Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL, http://dx.doi.org/10.1158/1538-7445.am2011-617

MacGregor S; Lu Y; Johnatty S; Beesley J; Chen XQ; Fridley B; Webb P; Gurney H; Harnett P; Haber M; Goode E; De Fazio A; Cheneyix-Trench G, 2011, 'A multi-stage genome-wide association study on response to chemotherapy in ovarian cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, presented at Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL, http://dx.doi.org/10.1158/1538-7445.AM2011-4679

Marshall GM; Gherardi S; Xu N; Neiron Z; Trahair T; Scarlett C; Chang DK; Liu PY; Jankowski K; Iraci N; Haber M; Norris MD; Stossi F; Katzenellenbogen BS; Biankin AV; Perini G; Liu T, 2010, 'Abstract 4869: Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects', in Cellular and Molecular Biology, American Association for Cancer Research, presented at Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC, http://dx.doi.org/10.1158/1538-7445.am10-4869

Lau DT; Murray J; Norris M; Marshall GM; Haber M; Ashton LJ, 2010, 'Abstract 888: Reduced folate carrier gene polymorphism (RFC 80G>A): Associations with clinical outcome in NMYC amplified neuroblastoma patients', in Epidemiology, American Association for Cancer Research, presented at Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC, http://dx.doi.org/10.1158/1538-7445.am10-888

Haber M; Porro A; Diolaiti D; Iraci N; Henderson M; Munoz M; Xue C; Flemming C; Murray J; London W; Buxton A; Ashton L; Cohn S; Schwab M; Marshall G; Della Valle G; Perini G; Norris M, 2009, 'A specific transcription signature of ABC transporter genes is dictated by Myc-family oncogenes: A powerful tool to predict clinical outcome', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209701803375&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Liu T; Neiron Z; Norris M; Haber M; Marshall G, 2009, 'The role of N-Myc-induced HDAC2 over-expression in neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209701802056&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Evageliou N; Vu A; Liu X; Manning R; Hayes C; Norris M; Marshall G; Haber M; Gilmour S; Hogarty M, 2009, 'Dual Targeting of AMD1 and ODC1 potently inhibits neuroblastoma initiation in vitro and in vivo', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209702803498&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sekyere E; Thomas W; Chui H; Keating J; Chen JB; Davis N; Cheung B; Raif A; Jankowski K; Cheng A; Kees U; Ellis T; Wainwright B; Norris M; Haber M; Trahair T; Shohet J; Ding H-F; Marshall G, 2009, 'Perinatal Myc signalling as a mechanism of embryonal cancer initiation', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209702603052&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Bell JL; Cheung BB; D'Andreti C; Koach J; Raif A; Thomas WD; Norris M; Haber M; Kavallaris M; Marshall GM, 2008, 'The role of the estrogen-responsive B box protein (EBBP) in cancer cell cycle progression', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, Lyon, FRANCE, pp. 95 - 95, presented at 20th Meeting of the European-Association-for-Cancer-Research, Lyon, FRANCE, 05 July 2008 - 08 July 2008, http://dx.doi.org/10.1016/S1359-6349(08)71542-8

Haber M; Cheng N; Smith J; Murray J; Hogarty MD; London WB; Marshall GM; Norris MD, 2008, 'Overexpression of ODC1 is associated with poor outcome in childhood neuroblastoma and represents an important therapeutic target', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1538-7445.AM2008-5832

Ambros PF; Ambros PF; Ambros IM; Brodeur GM; Haber M; Khan J; Nakagawara A; Schleiermacher G; Speleman F; Spitz R; Cohn SL; Pearson ADJ; Maris JM, 2007, 'International consensus for neuroblastoma molecular diagnostics: Report from the International Neuroblastoms Risk Grouping (INRG) biology committee', in PEDIATRIC BLOOD & CANCER, WILEY PERIODICALS, INC, pp. 432 - 433, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000249116100127&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Norris MD; Smith J; Kwek A; Flemming C; Cohn SL; London WB; Buxton A; Marshall GM; Haber M, 2007, 'Expression of the multidrug transporter genes ABCC1/MRP1, ABCC3/MRP3, and ABCC4/MRP4 are powerful predictors of clinical outcome in childhood neuroblastoma', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000455043702481&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Norris MD; Smith J; Flemming C; Lyn L; Allen J; Cohn SL; London WB; Buxton A; Marshhall GM; Haber M, 2006, 'The multidrug transporter MRP4/ABCC4 is a powerful marker of poor prognosis in neuroblastoma and a target for therapeutic suppression', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, pp. 121 - 121, http://dx.doi.org/10.1016/S1359-6349(06)70398-6

Thomas WD; Keating J; Cheung B; Armatai P; Weiss W; Norris M; Haber M; Marshall GM, 2006, 'Neuroblastoma tumor initiation: MYCN mediated mechanisms of resistance to cell death', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000454606201380&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ashton LJ; Murray JE; Marshall GM; Haber M; Ashley DM; Norris MD, 2006, 'Polymorphisms of glutathione-S-transferase and N-acetyltransferase genes and response to treatment in childhood neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000454606202297&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Cheung BB; Bell J; Raif A; Yan J; Roediger B; Smith S; Lee M; Thomas WD; Kavallaris M; Norris M; Haber M; Liu H-L; Zajchowski D; Marshall GM, 2006, 'Characterization of a novel regulator of the retinoid signal: The estrogen-responsive B box protein.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000454608804357&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Burkhart CA; Watt F; Pajic M; Murray J; Xue C; Flemming C; Smith J; Marshall GM; Haber M; Norris MD; Gudkov AV, 2006, 'Selective Sensitization of murine tumors to chemotherapy by a novel class of non-toxic small molecule inhibitors of MRP1', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000454606201252&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Laughton SJ; Ashton LJ; Kwan E; Norris MD; Haber M; Marshall GM, 2003, 'Early markers of the therapeutic index in children with acute lymphoblastic leukaemia predict outcome.', in BLOOD, AMER SOC HEMATOLOGY, SAN DIEGO, CALIFORNIA, pp. 879A - 879A, presented at 45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA, 06 December 2003 - 09 December 2003, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000186536703271&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Verrills N; Flemming C; Liu M; Ivery M; Norris MD; Haber M; Kavallaris M, 2002, 'Acquired beta-tubulin mutations affecting microtubule stability and drug binding', in MOLECULAR BIOLOGY OF THE CELL, AMER SOC CELL BIOLOGY, SAN FRANCISCO, CALIFORNIA, pp. 463A - 463A, presented at 42nd Annual Meeting of the American-Society-for-Cell-Biology, SAN FRANCISCO, CALIFORNIA, 14 December 2002 - 18 December 2002, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000179569102604&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lock RB; Liem N; Tajbakhsh M; Milross CG; Xue CY; Haber M; Norris MD; Marshall GM; Rice AM, 2001, 'Novel biological characteristics and disparate vincristine responses of primary childhood acute lymphoblastic leukemia cells engrafted into non-obese diabetic/severe combined immunodeficient mice.', in BLOOD, AMER SOC HEMATOLOGY, pp. 309A - 310A, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000172134101312&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

STEWART BW; BRIAN MJ; HABER M; NORRIS MD; WHITE L, 1988, 'THERAPY-INDUCED RESISTANCE TO BOTH METHOTREXATE AND SOME NATURAL PRODUCT DRUGS IN A HUMAN-LEUKEMIA LINE (LALW-2)', in PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, pp. 311 - 311, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1988N264701236&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Posters

Karsa M; Failes T; Arndt GM; Kees UR; Haber M; Norris MD; Sutton R; Lock RB; Somers K; Henderson MJ, 2018, 'PO-405 Repositioning existing drugs as novel therapeutics for high-risk paediatric leukaemia', in ESMO Open, Elsevier BV, Vol. 3, pp. A181 - A181, http://dx.doi.org/10.1136/esmoopen-2018-eacr25.431

Conference Presentations

Shahbazi J; Scarlett CJ; Norris M; Liu B; Haber M; Tee AE; Carrier A; Biankin AV; London WB; Marshall GM; Lock R; Liu T, 2014, 'Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, San Diego, CA, Vol. 74, presented at 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR), San Diego, CA, 05 April 2014 - 09 April 2014, http://dx.doi.org/10.1158/1538-7445.AM2014-5138

Conference Abstracts

Khan A; Gamble L; Upton D; Yu D; Ehteda A; Pandher R; Mayoh C; Burns M; Norris M; Haber M; Tsoli M; Ziegler D, 2020, 'DIPG-15. POLYAMINE PATHWAY INHIBITION IS A POTENT NOVEL THERAPEUTIC STRATEGY AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA', in Neuro-Oncology, Oxford University Press (OUP), Vol. 22, pp. iii289 - iii290, http://dx.doi.org/10.1093/neuonc/noaa222.065

Ehteda A; Franshaw L; Liu J; Joshi S; Simon S; Pang CNI; Giorgi F; Pandher R; Ung C; Tolhurst O; Mayoh C; Khan A; Hayden E; Gopalakrishnan A; Trebilcock P; Upton D; Lehmann R; George S; Vittorio O; Tsoli M; Gurova K; Gudkov AG; Norris MD; Haber M; Ziegler DS, 2020, 'DIPG-27. TARGETING FACILITATES CHROMATIN TRANSCRIPTION (FACT) AS A NOVEL STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) THAT ENHANCES RESPONSE TO HISTONE DEACETYLASE (HDAC) INHIBITION', in Neuro-Oncology, Oxford University Press (OUP), Vol. 22, pp. iii292 - iii292, http://dx.doi.org/10.1093/neuonc/noaa222.076

Khan A; Gamble L; Pandher R; Burns MR; Mussai F; Norris M; Haber M; Tsoli M; Ziegler DS, 2020, 'DIPG-16. COMBINATION OF ARGININE DEPLETION AND POLYAMINE INHIBITION AS AN ANTICANCER STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)', in Neuro-Oncology, Oxford University Press (OUP), Vol. 22, pp. iii290 - iii290, http://dx.doi.org/10.1093/neuonc/noaa222.066

Dong-Anh K-Q; Nagabushan S; Manoharan N; Arndt G; Barahona P; Cowley MJ; Ekert PG; Failes T; Bolanos NF; Gauthier M; Gifford AJ; Haber M; Kumar A; Lock RB; Marshall GM; Mayoh C; Mould E; Norris MD; Gopalakrishnan A; Omer N; Trebilcock P; Trahair TN; Tsoli M; Tucker K; Wong M; Tyrrell V; Lau L; Ziegler DS, 2020, 'PRECISION MEDICINE FOR PAEDIATRIC HIGH-GRADE DIFFUSE MIDLINE GLIOMAS - RESULTS FROM THE ZERO CHILDHOOD CANCER COMPREHENSIVE PRECISION MEDICINE PROGRAM', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 22, pp. 302 - 302, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000606080100118&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Barahona P; Fletcher J; Fuentes-Bolanos N; Gauthier M-E; Haber M; Lock RB; Marshall GM; Mayoh C; Mould E; Nagabushan S; Norris M; O’Brien T; Sherstyuk A; Thomas D; Trahair T; Tucker K; Warby M; Wong M; Ziegler DS; Tyrrell VJ; Ekert P; Cowley MJ; Lau L; Quang D-AK, 2020, 'Abstract A52: Zero Childhood Cancer (ZERO): A comprehensive precision medicine platform for children with high-risk cancer', in Poster Presentations - Proffered Abstracts, American Association for Cancer Research, presented at Abstracts: AACR Special Conference on the Advances in Pediatric Cancer Research; September 17-20, 2019; Montreal, QC, Canada, http://dx.doi.org/10.1158/1538-7445.pedca19-a52

Atkinson C; Tactacan C; Kamili A; Saletta F; Gana C; Eden G; Mayoh C; Lock R; Norris M; Haber M; Gifford A; Trahair T; Fletcher J, 2020, 'Abstract A35: P-Glycoprotein is a resistance mechanism for conventional induction chemotherapy but not ALK inhibitors in high-risk neuroblastoma', in Poster Presentations - Proffered Abstracts, American Association for Cancer Research, presented at Abstracts: AACR Special Conference on the Advances in Pediatric Cancer Research; September 17-20, 2019; Montreal, QC, Canada, http://dx.doi.org/10.1158/1538-7445.pedca19-a35

Haber M; Cowley MJ; Ekert P; Lau L; Mould E; Gifford A; Lock RB; Marshall GM; Norris MD; O'Brien T; Dong AKQ; Thomas D; Trahair T; Tucker K; Ziegler DS; Tyrrell V, 2020, 'Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer in Australia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, Vol. 80, presented at AACR Annual Meeting, ELECTR NETWORK, 22 June 2020 - 24 June 2020, http://dx.doi.org/10.1158/1538-7445.AM2020-SY09-02

Haber M; Gamble L; Xiao L; Pandher R; Somers K; Murray J; Khan A; Yu D; Franshaw L; Burns MR; Tsoli M; Ehteda A; Cesare A; O'Connor A; Mussai F; de Santo C; Cheng P; Korotchkina L; Gurova K; Tyrrell V; Mould E; Lau L; Dong AKQ; Mayoh C; Arndt G; Barahona P; Failes T; Fletcher J; Fuentes-Bolanos N; Gauthier M-E; Gifford A; Grebert-Wade D; Kamili A; Kumar A; Nagabushan S; O'Brien T; Strong P; Sherstyuk A; Thomas D; Trahair T; Tucker K; Warby M; Wong M; Xie J; Evans K; Lock R; Chernova OB; Henderson M; Gudkov AV; Ekert P; Cowley MJ; Marshall GM; Ziegler DS; Norris MD, 2019, 'Molecular targeted therapies and precision medicine for children with neuroblastoma and other refractory malignancies', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Montreal, CANADA, Vol. 80, pp. 23 - 24, presented at AACR Special Conference on the Advances in Pediatric Cancer Research, Montreal, CANADA, 17 September 2019 - 20 September 2019, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000551367400013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Atkinson C; Tactacan C; Kamili A; Saletta F; Gana C; Eden G; Mayoh C; Lock R; Norris M; Haber M; Gifford A; Trahair T; Fletcher J, 2019, 'P-Glycoprotein is a resistance mechanism for conventional induction chemotherapy but not ALK inhibitors in high-risk neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Montreal, CANADA, Vol. 80, pp. 61 - 61, presented at AACR Special Conference on the Advances in Pediatric Cancer Research, Montreal, CANADA, 17 September 2019 - 20 September 2019, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000551367400079&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Atkinson C; Tactacan CM; Kamili A; Saletta F; Gana C; Eden GL; Mayoh C; Lock RB; Norris MD; Haber M; Gifford AJ; Trahair TN; Fletcher JI, 2019, 'Abstract 4741: Re-evaluating the role of P-glycoprotein in the resistance of high-risk neuroblastoma to standard-of-care chemotherapies', in Experimental and Molecular Therapeutics, American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.am2019-4741

Kamili A; Gifford AJ; Li N; Mayoh C; Eden GL; Xie J; Lukeis RE; Norris MD; Haber M; McCowage G; Trahair TN; Fletcher JI, 2019, 'Abstract 2884: Establishment of patient-derived xenograft models for high-risk neuroblastoma', in Tumor Biology, American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.sabcs18-2884

Tsoli M; Lau L; Barahona P; Mayoh C; Failes T; Wong M; Sherstyuk A; Gifford AJ; Kumar A; Mould E; Ung C; Tolhurst O; Gopalakrishnan A; Grebert-Wade D; Strong P; Trebilcock P; Lock R; Tyrrell V; Trahair T; Tucker K; Warby M; Arndt G; Norris M; Haber M; Marshall G; O'Brien T; Dong AKQ; Cowley M; Ekert P; Ziegler DS, 2019, 'RESULTS OF THE ZERO CHILDHOOD CANCER INTEGRA-TM PRECISION MEDICINE PLATFORM FOR PAEDIATRIC HIGH-RISK BRAIN TUMOURS', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, San Francisco, CA, Vol. 21, pp. 118 - 118, presented at 5th Biennial Conference of the Society-for-Neuro-Oncology on Pediatric Neuro-Oncology Basic and Translational Research, San Francisco, CA, 03 May 2019 - 04 May 2019, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000473243700229&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mould EV; Lau L; Arndt G; Barahona P; Cowley MJ; Ekert P; Failes T; Fletcher J; Gifford A; Grebert-Wade D; Haber M; Kamili A; Kumar A; Lock RB; Marshall GM; Mayoh C; Norris M; O'Brien T; Quang DAK; Strong P; Sherstyuk A; Trahair T; Tsoli M; Tucker K; Warby M; Wong M; Xie J; Ziegler DS; Tyrrell V, 2019, 'Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Atlanta, GA, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Atlanta, GA, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-3111

Atkinson C; Tactacan CM; Kamili A; Saletta F; Gana C; Eden GL; Mayoh C; Lock RB; Norris MD; Haber M; Gifford AJ; Trahair TN; Fletcher JI, 2019, 'Re-evaluating the role of P-glycoprotein in the resistance of high-risk neuroblastoma to standard-of-care chemotherapies', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Atlanta, GA, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Atlanta, GA, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.SABCS18-4741

Kamili A; Gifford AJ; Li N; Mayoh C; Eden GL; Xie J; Lukeis RE; Norris MD; Haber M; McCowage G; Trahair TN; Fletcher JI, 2019, 'Establishment of patient-derived xenograft models for high-risk neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Atlanta, GA, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Atlanta, GA, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-2884

Nagy Z; Kanikevichi M; Koachi J; Mayoh C; Carter D; Liu T; Du Y; Jiang C; Haber M; Norris M; Cheung B; Marshall G, 2019, 'Alyref is a novel binding partner and co-factor for MYCN-driven oncogenesis in neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Atlanta, GA, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Atlanta, GA, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-3659

Khan A; Gamble L; Yu D; Joshi S; Franshaw L; Burns M; Norris M; Haber M; Tsoli M; Ziegler D, 2018, 'TARGETING THE POLYAMINE PATHWAY AS A NOVEL THERAPEUTIC TREATMENT AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Denver, CO, Vol. 20, pp. 49 - 49, presented at 18th International Symposium on Pediatric Neuro-Oncology (ISPNO), Denver, CO, 30 June 2018 - 03 July 2018, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000438339000097&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ziegler D; Tsoli M; Tyrell V; Cohn R; Lau L; Cox M; Cowley M; Ekert P; Marshall G; Haber M, 2018, 'EAPH-09. POTENT CLINICAL AND RADIOLOGICAL RESPONSE TO LAROTRECTINIB IN FIRST CASE OF TRK FUSION HIGH GRADE GLIOMA', in Neuro-Oncology, Oxford University Press (OUP), Vol. 20, pp. i67 - i67, http://dx.doi.org/10.1093/neuonc/noy059.178

Khan A; Gamble L; Yu D; Joshi S; Franshaw L; Burns M; Norris M; Haber M; Tsoli M; Ziegler D, 2018, 'DIPG-01. TARGETING THE POLYAMINE PATHWAY AS A NOVEL THERAPEUTIC TREATMENT AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA', in Neuro-Oncology, Oxford University Press (OUP), Vol. 20, pp. i49 - i49, http://dx.doi.org/10.1093/neuonc/noy059.095

Khan A; Tsoli M; Yu D; Joshi S; Gamble L; Franshaw L; Haber M; Ziegler DS, 2018, 'Targeting the polyamine pathway as a novel therapeutic treatment against diffuse intrinsic pontine glioma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Chicago, IL, Vol. 78, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Chicago, IL, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-4800

Karsa M; Somers K; Mariana A; Failes T; Arndt GM; Kees UR; Haber M; Norris MD; Sutton R; Lock RB; Henderson MJ, 2017, 'REPOSITIONING EXISTING DRUGS AS NOVEL THERAPEUTICS: OXIDATIVE STRESS AS A TARGET FOR HIGH-RISK LEUKAEMIA IN CHILDREN', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, Madrid, SPAIN, Vol. 102, pp. 27 - 27, presented at 22nd Congress of the European-Hematology-Association, Madrid, SPAIN, 22 June 2017 - 25 June 2017, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000404127001055&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lau L; Byrne J; Ekert PG; Failes T; Fellowes A; Fletcher J; Gifford A; Haber M; Kumar A; Lock R; Marshall G; McCowage GB; Mould E; Norris M; Trahair T; Tsoli M; Tyrrell V; Wadham C; Xie J; Ziegler DS, 2017, 'Pilot study of a comprehensive precision medicine platform for children with high-risk cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, Chicago, IL, Vol. 35, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 02 June 2017 - 06 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.10539

Ehteda A; Tsoli M; Chitranjan A; Chang C; Simon S; Kankean A; Shen H; Liu J; Haber M; Gudkov A; Ziegler D, 2016, 'HG-20COMBINATION OF EPIGENETIC MODIFIERS CBL0137 AND PANOBINOSTAT IS HIGHLY POTENT IN VITRO AND IN VIVO FOR DIFFUSE INTRINSIC PONTINE GLIOMA', in Neuro-Oncology, Oxford University Press (OUP), Vol. 18, pp. iii51.4 - iii51, http://dx.doi.org/10.1093/neuonc/now073.17

Chudakova D; Somers K; Middlemiss S; Wen V; Kwek A; Liu B; Clifton M; Pan S; Cruikshank S; Scandlyn M; Failes T; Hoang W; Kees U; Chernova O; Gudkov AV; Haber M; Norris M; Henderson M, 2015, 'Selective and rapid killing of mixed lineage leukemia and CALM-AF10 leukemia by SM7, a novel small molecule identified by chemical library screening', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Fort Lauderdale, FL, Vol. 76, presented at AACR Special Conference on Advances in Pediatric Cancer Research - From Mechanisms and Models to Treatment and Survivorship, Fort Lauderdale, FL, 09 November 2015 - 12 November 2015, http://dx.doi.org/10.1158/1538-7445.PEDCA15-B23

Tee AE; Liu P; Maag J; Song R; Li J; Cheung BB; Haber M; Norris MD; Marshall GM; Dinger M; Liu T, 2015, 'The long noncoding RNA MALAT1 promotes hypoxia-driven angiogenesis by upregulating pro-angiogenic gene expression in neuroblastoma cells', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Philadelphia, PA, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Philadelphia, PA, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-146

Haber M; Murray J; Gamble L; Carnegie-Clark A; Webber H; Ruhle M; Henderson MJ; Middlemass S; Carter D; Tsoli M; Ehteda A; Simon S; Oberthuer A; Fischer M; Gurova K; Burkhart C; Purmal A; Lock RB; Ziegler D; Marshall GM; Gudkov AV; Norris MD, 2015, 'The FACT histone chaperone complex is highly expressed in aggressive drug refractory childhood cancers and the anti-FACT compound CBL0137 represents a highly promising therapeutic approach in this setting', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Philadelphia, PA, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Philadelphia, PA, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-1611

Neiron Z; Jankowski K; Murray J; Champion S; Norris MD; Haber M; Fletcher JI, 2011, 'Development of organ-selective neuroblastoma cell lines to identify genes mediating bone marrow and liver colonization', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 71, http://dx.doi.org/10.1158/1538-7445.AM2011-5237

Marshall GM; Liu PY; Gherardi S; Scarlett CJ; Bedalov A; Xu N; Iraci N; MacKenzie KL; Haber M; Norris MD; Biankin AV; Perini G; Liu T, 2011, 'SIRT1 promotes N-Myc oncogenesis stabilizing N-Myc protein', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 71, http://dx.doi.org/10.1158/1538-7445.AM2011-3027

Sutton R; Venn NC; Kilo T; Bhadri V; Pozza LD; Marshall GM; Haber M; Norris MD; Shaw P, 2008, 'The value of monitoring for minimal residual disease post-transplant in children with acute lymphoblastic leukaemia', in British Journal of Haematology, Blackwell Publishing Ltd, Oxford, England, Vol. 141, pp. 102 - 102, presented at Abstracts of the British Society of Haematology 48th Annual Scientific Meeting, incorporating the 6th Bi-Annual I-BFM Leukaemia Symposium, Glasgow, SCOTLAND, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000255032500279&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Choi S; Kwan E; Beesley A; Sutton R; Lock RB; Papa R; Marshall GM; Kees UR; Haber M; Norris MD, 2006, 'Relapse in children with acute lymphoblastic leukaemia is associated with selection of a pre-existing drug resistance subclone', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, Vol. 4, pp. 81 - 81, http://dx.doi.org/10.1016/S1359-6349(06)70257-9

Murray J; Burkhart CA; Watt F; Pajic M; Flemming C; Smith J; Gudkov AV; Haber M; Norris MD, 2006, 'Sensitisation of neuroblastorna tumours to chemotherapy by use of a novel class of MRP1 small molecule inhibitor', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, Vol. 4, pp. 54 - 54, http://dx.doi.org/10.1016/S1359-6349(06)70175-6

STEWART BW; KAVALLARIS M; SMITH GJ; HABER M, 1985, 'MONITORING REPAIR AND REPLICATIVE-INDUCED STRUCTURAL-CHANGE IN CULTURES OF PROLIFERATING MAMMALIAN-CELLS', in MEDICAL AND PEDIATRIC ONCOLOGY, WILEY-LISS, Vol. 13, pp. 135 - 135, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1985AHS3500014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Preprints

Rokita JL; Rathi KS; Cardenas MF; Upton KA; Jayaseelan J; Cross KL; Pfeil J; Ritenour LE; Modi A; Farrel A; Way GP; Kendsersky NM; Patel K; Lopez G; Vaksman Z; Mayoh C; Nance J; McCoy K; Haber M; Evans K; McCalmont H; Bendak K; Böhm JW; Marshall GM; Tyrrell V; Kalletla K; Braun FK; Qi L; Du Y; Zhang H; Lindsay HB; Zhao S; Shu J; Baxter P; Morton C; Kurmashev D; Zheng S; Chen Y; Bowen J; Bryan AC; Leraas KM; Coppens SE; Doddapaneni H; Momin Z; Zhang W; Sacks GI; Hart LS; Krytska K; Mosse YP; Gatto GJ; Sanchez Y; Greene CS; Diskin SJ; Vaske OM; Haussler D; Gastier-Foster JM; Kolb EA; Gorlick R; Li X-N; Reynolds CP; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB; Raman P; Wheeler DA; Maris JM, Genomic profiling of childhood tumor patient-derived xenograft models to enable rational clinical trial design, http://dx.doi.org/10.1101/566455

Fareh M; Hu W; Kumar A; Qi S; Sadras T; Casan J; Ma D; Brown L; Haber M; Voskoboinik I; Trapani J; Ekert P, Single-base precision design of CRISPR-Cas13b enables systematic silencing of oncogenic fusions, http://dx.doi.org/10.21203/rs.3.rs-1714034/v1

School of Women's and Children's Health

Professor Michelle Haber

Tabs

Study @ WCH

Research @ WCH

Quick Links

Connect